Abstract
Background
Circular RNAs (circRNAs) are important participators in tumor progression for their stable structure and high tissue-specific expression. The purpose of this research was to clarify the potential and mechanism of a novel circRNA-circ-HSP90A in non-small cell lung cancer (NSCLC).
Methods
Biological potentials of circ-HSP90A in NSCLC were measured by functional assays. Molecular interaction was assessed by bioinformatics analysis and mechanical assays.
Results
Results depicted that circ-HSP90A was cyclization from its host gene heat shock protein 90 alpha (HSP90A) and was up-regulated in NSCLC cells. Circ-HSP90A depletion retarded proliferation, migration, invasion, and immune evasion. Mechanistically, circ-HSP90A recruited ubiquitin specific peptidase 30 (USP30) to stabilize HSP90A and then stimulated the signal transducer and activator of transcription 3 (STAT3) signaling. Meanwhile, circ-HSP90A sponged miR-424-5p to programmed cell death ligand 1 (PD-L1).
Conclusions
Our study firstly showed that circ-HSP90A promoted cell growth, stemness, and immune evasion in NSCLC through regulating STAT3 signaling and programmed cell death 1 (PD-1)/PD-L1 checkpoint, mirroring that targeting circ-HSP90A might become a novel target of immunotherapy in NSCLC.
Supplementary Information
The online version contains supplementary material available at 10.1007/s00262-022-03235-z.
Keywords: Non-small cell lung cancer, Circ-HSP90A, PD-1/PD-L1, STAT3
Introduction
Non-small cell lung cancer (NSCLC), a subtype of lung cancer, is a dominating cause of disease-concerned death all around the world [1]. Although tremendous advances have been made in the diagnosis and treatments of lung cancer, the 5-year survival rate of NSCLC sufferers is less than 20% [2]. In recent years, tumor immune microenvironment exerts a vital part in NSCLC development, and NSCLC cells can cooperate with immune cells to promote immune evasion [3]. Therefore, cancer immunotherapies have been adopted to treat NSCLC in clinical trials, among which, programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) blockade has been recognized to be one of a novel cancer immunotherapies for NSCLC treatment [4]. PD-L1 can bind to PD-1 to repress the activity and induce CD8+ T cells apoptosis, resulting in the immune evasion of tumors [5]. As a result, understanding the potential mechanism related to PD-1/PD-L1 checkpoint in NSCLC is conducive to improve the immunotherapy for NSCLC.
Recently, studies on circular RNAs (circRNAs) have emerged as a popular subject in tumors. CircRNAs are a special type of noncoding RNAs and are formed by a covalently closed continuous loops [6, 7]. Abnormal expression of circRNAs has been served as promising prognostic indicators for multiple cancers, such as gastric cancer [8], triple-negative breast cancer [9] and ovarian cancer [10]. Mounting evidence has demonstrated that circRNAs are implicated in modulating cancer progression via sponging microRNAs (miRNAs) or cooperating with RNA-binding proteins (RBPs) [11]. Additionally, circRNAs are important participants in cell proliferation, apoptosis, migration, and invasion of NSCLC. For instance, circRNA 100,146 facilitates NSCLC cell proliferation and invasion via targeting miR-361-3p and miR-615-5p [12]. Circ_0078767 restrains cell cycle progression in NSCLC by the miR-330-3p/RASSF1A axis [13]. Circ-CPA4 facilitates cell growth and immune evasion in NSCLC via increasing PD-L1 expression (14). However, the potential of circRNAs in NSCLC has not been fully elucidated yet.
Signal transducer and activator of transcription 3 (STAT3) is geared to the STAT family and is activated in various cancers, including NSCLC [15]. Upon activation, STAT3 undergoes phosphorylation-induced dimerization, nuclear translocation and combination with its target genes, therefore inducing the transcription of downstream target genes and cancer progression [16]. As a consequence, inhibitors targeting STAT3 activation have provided promise in repressing cancer development and have been extensively investigated in cancers, NSCLC included [17]. Accumulating evidence has suggested that circRNAs are implicated in NSCLC progression via regulating STAT3. Yu Dong et al. have pointed that circ_0076305 influences cisplatin resistance of NSCLC via positively modulating STAT3 [18]. CircHIPK3 influences autophagy by STAT3 signaling in NSCLC [19].
In this study, we investigated a circRNA derived from its host gene heat shock protein 90 alpha (HSP90A) in NSCLC. We probed the function of circ-HSP90A on NSCLC progression and immune evasion. Moreover, the relation between circ-HSP90A with PD-L1 and STAT3 was also explored further. Our findings might provide potential therapeutic targets for this cancer.
Material and methods
Cell culture
NSCLC cells (H1299, A549, PC9, CAL-12T, and H1915), normal human lung epithelial cells (BEAS-2B), and human embryonic kidney cells (HEK293T) were offered from the Shanghai Institutes for Biological Sciences of the Chinese Academy of Sciences. H1299, PC9 as well as H1915 cells were grown in RPMI-1640 medium (Gibco, Rockville, MD, USA). A549 cells were grown in F-12K medium (Gibco). CAL-12T and HEK293T cells were cultured in DMEM. BEAS-2B cells were grown in BEGM (Lonza/Clonetics Corporation). All mediums were contained 10% fetal bovine serum with 5% CO2 at 37 °C.
Reagents
The cycloheximide (CHX; 5 µM), MG132 (10 Μm), RNase R (40 U), and actinomycin D (4 µg/ml) were obtained from Sigma-Aldrich (St. Louis, MO, USA).
Quantitative real-time polymerase chain reaction (RT-qPCR)
Extraction of total RNA was used with a TRIzol reagent (Invitrogen) and then performed cDNA synthesis via M-MLV reverse transcriptase (Applied Biosystems, USA). qPCR was utilized to detect relative expression with SYBR Premix Ex Taq II (Takara, Tokyo, Japan) and calculated using 2−∆∆Ct method, which was normalized for GAPDH or U6. The sequences used in the experiments are listed in Table 1.
Table 1.
Primers | Sequences (5′ > 3′) |
---|---|
hsa_circ_0033393 | GCATTGGACAAAATCCGGTATGAAAGCTTGACAGATCCCAGTAAATTAGACTCTGGGAAAGAGCTGCATATTAACCTTATACCGAACAAACAAGATCGAACTCTCACTATTGTGGATACTGGAATTGGAATGACCAAGGCTGACTTGATCAATAACCTTGGTACTATCGCCAAGTCTGGGACCAAAGCGTTCATGGAAGCTTTGCAGGCTGGTGCAGATATCTCTATGATTGGCCAGTTCGGTGTTGGTTTTTATTCTGCTTATTTGGTTGCTGAGAAAGTAACTGTGATCACCAAACATAACGATGATGAGCAGTACGCTTGGGAGTCCTCAGCAGGGGGATCATTCACAGTGAGGACAGACACAGGTGAACCTATGGGTCGTGGAACAAAAGTTATCCTACACCTGAAAGAAGACCAAACTGAGTACTTGGAGGAACGAAGAATAAAGGAGATTGTGAAGAAACATTCTCAGTTTATTGGATATCCCATTACTCTTTTTGTGGAGAAGGAACGTGATAAAGAAGTAAGCGATGATGAGGCTGAAGAAAAGGAAGACAAAGAAGAAGAAAAAGAAAAAGAAGAGAAAGAGTCGGAAGACAAACCTGAAATTGAAGATGTTGGTTCTGATGAGGAAGAAGAAAAGAAGGATGGTGACAAGAAGAAGAAGAAGAAGATTAAGGAAAAGTACATCGATCAAGAAGAGCTCAACAAAACAAAGCCCATCTGGACCAGAAATCCCGACGATATTACTAATGAGGAGTACGGAGAATTCTATAAGAGCTTGACCAATGACTGGGAAGATCACTTGGCAGTGAAGCATTTTTCAGTTGAAGGACAGTTGGAATTCAGAGCCCTTCTATTTGTCCCACGACGTGCTCCTTTTGATCTGTTTGAAAACAGAAAGAAAAAGAACAACATCAAATTGTATGTACGCAGAGTTTTCATCATGGATAACTGTGAGGAGCTAATCCCTGAATATCTGAACTTCATTAGAGGGGTGGTAGACTCGGAGGATCTCCCTCTAAACATATCCCGTGAGATGTTGCAACAAAGCAAAATTTTGAAAGTTATCAGGAAGAATTTGGTCAAAAAATGCTTAGAACTCTTTACTGAACTGGCGGAAGATAAAGAGAACTACAAGAAATTCTATGAGCAGTTCTCTAAAAACATAAAGCTTGGAATACACGAAGACTCTCAAAATCGGAAGAAGCTTTCAGAGCTGTTAAGGTACTACACATCTGCCTCTGGTGATGAGATGGTTTCTCTCAAGGACTACTGCACCAGAATGAAGGAGAACCAGAAACATATCTATTATATCACAGGTGAGACCAAGGACCAGGTAGCTAACTCAGCCTTTGTGGAACGTCTTCGGAAACATGGCTTAGAAGTGATCTATATGATTGAGCCCATTGATGAGTACTGTGTCCAACAGCTGAAGGAATTTGAGGGGAAGACTTTAGTGTCAGTCACCAAAGAAGGCCTGGAACTTCCAGAGGATGAAGAAGAGAAAAAGAAGCAGGAAGAGAAAAAAACAAAGTTTGAGAACCTCTGCAAAATCATGAAAGACATATTGGAGAAAAAAGTTGAAAAGGTGGTTGTGTCAAACCGATTGGTGACATCTCCATGCTGTATTGTCACAAGCACATATGGCTGGACAGCAAACATGGAGAGAATCATGAAAGCTCAAGCCCTAAGAGACAACTCAACAATGGGTTACATGGCAGCAAAGAAACACCTGGAGATAAACCCTGACCATTCCATTATTGAGACCTTAAGGCAAAAGGCAGAGGCTGATAAGAACGACAAGTCTGTGAAGGATCTGGTCATCTTGCTTTATGAAACTGCGCTCCTGTCTTCTGGCTTCAGTCTGGAAGATCCCCAGACACATGCTAACAGGATCTACAGGATGATCAAACTTGGTCTGGGTATTGATGAAGATGACCCTACTGCTGATGATACCAGTGCTGCTGTAACTGAAGAAATGCCACCCCTTGAAGGAGATGACGACACATCACGCATGGAAGAAGTAGACTAATCTCTGGCTGAGGGATGACTTACCTGTTCAGTACTCTACAATTCCTCTGATAATATATTTTCAAGGATGTTTTTCTTTATTTTTGTTAATATTAAAAAGTCTGTATGGCATGACAACTACTTTAAGGGGAAGATAAGATTTCTGTCTACTAAGTGATGCTGTGATACCTTAGGCACTAAAGCAGAGCTAGTAATGCTTTTTGAGTTTCATGTTGGTTTATTTTCACAGATTGGGGTAACGTGCACTGTAAGACGTATGTAACATGATGTTAACTTTGTGGTCTAAAGTGTTTAGCTGTCAAGCCGGATGCCTAAGTAGACCAAATCTTGTTATTGAAGTGTTCTGAGCTGTATCTTGATGTTTAGAAAAGTATTCGTTACATCTTGTAGGATCTACTTTTTGAACTTTTCATTCCCTGTAGTTGACAATTCTGCATGTACTAGTCCTCTAGAAATAGGTTAAACTGAAGCAACTTGATGGAAGGATCTCTCCACAGGGCTTGTTTTCCAAAGAAAAGTATTGTTTGGAGGAGCAAAGTTAAAAGCCTACCTAAGCATATCGTAAAGCTGTTCAAAAATAACTCAGACCCAGTCTTGTGGATGGAAATGTAGTGCTCGAGTCACATTCTGCTTAAAGTTGTAACAAATACAGATGAGTTAAAAGATATTGTGTGACAGTGTCTTATTTAGGGGGAAAGGGGAGTATCTGGATGACAGTTAGTGCCAAAATGTAAAACATGAGGCGCTAGCAGGAGATGGTTAAACACTAGCTGCTCCAAGGGTTGACATGGTCTTCCCAGCATGTACTCAGCAGGTGTGGGGTGGAGCACACGTAGGCACAGAAAACAGGAATGCAGACAACATGCATCCCCTGCGTCCATGAGTTACATGTGTTCTCTTAGTGTCCACGTTGTTTTGATGTTATTCATGGAATACCTTCTGTGTTAAATACAGTCACTTAATTCCTTGGCCTTA |
hsa_circ_0033386 | GTGGTTGTGTCAAACCGATTGGTGACATCTCCATGCTGTATTGTCACAAGCACATATGGCTGGACAGCAAACATGGAGAGAATCATGAAAGCTCAAGCCCTAAGAGACAACTCAACAATGGGTTACATGGCAGCAAAGAAACACCTGGAGATAAACCCTGACCATTCCATTATTGAGACCTTAAGGCAAAAGGCAGAGGCTGATAAGAACGACAAGTCTGTGAAGGATCTGGTCATCTTGCTTTATGAAACTGCGCTCCTGTCTTCTGGCTTCAGTCTGGAAGATCCCCAGACACATGCTAACAGGATCTACAGGATGATCAAACTTGGTCTGGGTATTGATGAAGATGACCCTACTGCTGATGATACCAGTGCTGCTGTAACTGAAGAAATGCCACCCCTTGAAGGAGATGACGACACATCACGCATGGAAGAAGTAGACTAATCTCTGGCTGAGGGATGACTTACCTGTTCAGTACTCTACAATTCCTCTGATAATATATTTTCAAGGATGTTTTTCTTTATTTTTGTTAATATTAAAAAGTCTGTATGGCATGACAACTACTTTAAGGGGAAGATAAGATTTCTGTCTACTAAGTGATGCTGTGATACCTTAGGCACTAAAGCAGAGCTAGTAATGCTTTTTGAGTTTCATGTTGGTTTATTTTCACAGATTGGGGTAACGTGCACTGTAAGACGTATGTAACATGATGTTAACTTTGTGGTCTAAAGTGTTTAGCTGTCAAGCCGGATGCCTAAGTAGACCAAATCTTGTTATTGAAGTGTTCTGAGCTGTATCTTGATGTTTAGAAAAGTATTCGTTACATCTTGTAGGATCTACTTTTTGAACTTTTCATTCCCTGTAGTTGACAATTCTGCATGTACTAGTCCTCTAGAAATAGGTTAAACTGAAGCAACTTGATGGAAGGATCTCTCCACAGGGCTTGTTTTCCAAAGAAAAGTATTGTTTGGAGGAGCAAAGTTAAAAGCCTACCTAAGCATATCGTAAAGCTGTTCAAAAATAACTCAGACCCAGTCTTGTGGATGGAAATGTAGTGCTCGAGTCACATTCTGCTTAAAGTTGTAACAAATACAGATGAGTTAAAAGATATTGTGTGACAGTGTCTTATTTAGGGGGAAAGGGGAGTATCTGGATGACAGTTAGTGCCAAAATGTAAAACATGAGGCGCTAGCAGGAGATGGTTAAACACTAGCTGCTCCAAGGGTTGACATGGTCTTCCCAGCATGTACTCAGCAGGTGTGGGGTGGAGCACACGTAGGCACAGAAAACAGGAATGCAGACAACATGCATCCCCTGCGTCCATGAGTTACATGTGTTCTCTTAGTGTCCACGTTGTTTTGATGTTATTCATGGAATACCTTCTGTGTTAAATACAGTCACTTAATTCCTTGGCCTTA |
hsa_circ_0033387 | GTGAGACCAAGGACCAGGTAGCTAACTCAGCCTTTGTGGAACGTCTTCGGAAACATGGCTTAGAAGTGATCTATATGATTGAGCCCATTGATGAGTACTGTGTCCAACAGCTGAAGGAATTTGAGGGGAAGACTTTAGTGTCAGTCACCAAAGAAGGCCTGGAACTTCCAGAGGATGAAGAAGAGAAAAAGAAGCAGGAAGAGAAAAAAACAAAGTTTGAGAACCTCTGCAAAATCATGAAAGACATATTGGAGAAAAAAGTTGAAAAGGTGGTTGTGTCAAACCGATTGGTGACATCTCCATGCTGTATTGTCACAAGCACATATGGCTGGACAGCAAACATGGAGAGAATCATGAAAGCTCAAGCCCTAAGAGACAACTCAACAATGGGTTACATGGCAGCAAAGAAACACCTGGAGATAAACCCTGACCATTCCATTATTGAGACCTTAAGGCAAAAGGCAGAGGCTGATAAGAACGACAAGTCTGTGAAGGATCTGGTCATCTTGCTTTATGAAACTGCGCTCCTGTCTTCTGGCTTCAGTCTGGAAGATCCCCAGACACATGCTAACAGGATCTACAGGATGATCAAACTTGGTCTGGGTATTGATGAAGATGACCCTACTGCTGATGATACCAGTGCTGCTGTAACTGAAGAAATGCCACCCCTTGAAGGAGATGACGACACATCACGCATGGAAGAAGTAGACTAATCTCTGGCTGAGGGATGACTTACCTGTTCAGTACTCTACAATTCCTCTGATAATATATTTTCAAGGATGTTTTTCTTTATTTTTGTTAATATTAAAAAGTCTGTATGGCATGACAACTACTTTAAGGGGAAGATAAGATTTCTGTCTACTAAGTGATGCTGTGATACCTTAGGCACTAAAGCAGAGCTAGTAATGCTTTTTGAGTTTCATGTTGGTTTATTTTCACAGATTGGGGTAACGTGCACTGTAAGACGTATGTAACATGATGTTAACTTTGTGGTCTAAAGTGTTTAGCTGTCAAGCCGGATGCCTAAGTAGACCAAATCTTGTTATTGAAGTGTTCTGAGCTGTATCTTGATGTTTAGAAAAGTATTCGTTACATCTTGTAGGATCTACTTTTTGAACTTTTCATTCCCTGTAGTTGACAATTCTGCATGTACTAGTCCTCTAGAAATAGGTTAAACTGAAGCAACTTGATGGAAGGATCTCTCCACAGGGCTTGTTTTCCAAAGAAAAGTATTGTTTGGAGGAGCAAAGTTAAAAGCCTACCTAAGCATATCGTAAAGCTGTTCAAAAATAACTCAGACCCAGTCTTGTGGATGGAAATGTAGTGCTCGAGTCACATTCTGCTTAAAGTTGTAACAAATACAGATGAGTTAAAAGATATTGTGTGACAGTGTCTTATTTAGGGGGAAAGGGGAGTATCTGGATGACAGTTAGTGCCAAAATGTAAAACATGAGGCGCTAGCAGGAGATGGTTAAACACTAGCTGCTCCAAGGGTTGACATGGTCTTCCCAGCATGTACTCAGCAGGTGTGGGGTGGAGCACACGTAGGCACAGAAAACAGGAATGCAGACAACATGCATCCCCTGCGTCCATGAGTTACATGTGTTCTCTTAGTGTCCACGTTGTTTTGATGTTATTCATGGAATACCTTCTGTGTTAAATACAGTCACTTAATTCCTTGGCCTTA |
hsa_circ_0033388 | CTTGGAATACACGAAGACTCTCAAAATCGGAAGAAGCTTTCAGAGCTGTTAAGGTACTACACATCTGCCTCTGGTGATGAGATGGTTTCTCTCAAGGACTACTGCACCAGAATGAAGGAGAACCAGAAACATATCTATTATATCACAGGTGAGACCAAGGACCAGGTAGCTAACTCAGCCTTTGTGGAACGTCTTCGGAAACATGGCTTAGAAGTGATCTATATGATTGAGCCCATTGATGAGTACTGTGTCCAACAGCTGAAGGAATTTGAGGGGAAGACTTTAGTGTCAGTCACCAAAGAAGGCCTGGAACTTCCAGAGGATGAAGAAGAGAAAAAGAAGCAGGAAGAGAAAAAAACAAAGTTTGAGAACCTCTGCAAAATCATGAAAGACATATTGGAGAAAAAAGTTGAAAAGGTGGTTGTGTCAAACCGATTGGTGACATCTCCATGCTGTATTGTCACAAGCACATATGGCTGGACAGCAAACATGGAGAGAATCATGAAAGCTCAAGCCCTAAGAGACAACTCAACAATGGGTTACATGGCAGCAAAGAAACACCTGGAGATAAACCCTGACCATTCCATTATTGAGACCTTAAGGCAAAAGGCAGAGGCTGATAAGAACGACAAGTCTGTGAAGGATCTGGTCATCTTGCTTTATGAAACTGCGCTCCTGTCTTCTGGCTTCAGTCTGGAAGATCCCCAGACACATGCTAACAGGATCTACAGGATGATCAAACTTGGTCTGGGTATTGATGAAGATGACCCTACTGCTGATGATACCAGTGCTGCTGTAACTGAAGAAATGCCACCCCTTGAAGGAGATGACGACACATCACGCATGGAAGAAGTAGACTAATCTCTGGCTGAGGGATGACTTACCTGTTCAGTACTCTACAATTCCTCTGATAATATATTTTCAAGGATGTTTTTCTTTATTTTTGTTAATATTAAAAAGTCTGTATGGCATGACAACTACTTTAAGGGGAAGATAAGATTTCTGTCTACTAAGTGATGCTGTGATACCTTAGGCACTAAAGCAGAGCTAGTAATGCTTTTTGAGTTTCATGTTGGTTTATTTTCACAGATTGGGGTAACGTGCACTGTAAGACGTATGTAACATGATGTTAACTTTGTGGTCTAAAGTGTTTAGCTGTCAAGCCGGATGCCTAAGTAGACCAAATCTTGTTATTGAAGTGTTCTGAGCTGTATCTTGATGTTTAGAAAAGTATTCGTTACATCTTGTAGGATCTACTTTTTGAACTTTTCATTCCCTGTAGTTGACAATTCTGCATGTACTAGTCCTCTAGAAATAGGTTAAACTGAAGCAACTTGATGGAAGGATCTCTCCACAGGGCTTGTTTTCCAAAGAAAAGTATTGTTTGGAGGAGCAAAGTTAAAAGCCTACCTAAGCATATCGTAAAGCTGTTCAAAAATAACTCAGACCCAGTCTTGTGGATGGAAATGTAGTGCTCGAGTCACATTCTGCTTAAAGTTGTAACAAATACAGATGAGTTAAAAGATATTGTGTGACAGTGTCTTATTTAGGGGGAAAGGGGAGTATCTGGATGACAGTTAGTGCCAAAATGTAAAACATGAGGCGCTAGCAGGAGATGGTTAAACACTAGCTGCTCCAAGGGTTGACATGGTCTTCCCAGCATGTACTCAGCAGGTGTGGGGTGGAGCACACGTAGGCACAGAAAACAGGAATGCAGACAACATGCATCCCCTGCGTCCATGAGTTACATGTGTTCTCTTAGTGTCCACGTTGTTTTGATGTTATTCATGGAATACCTTCTGTGTTAAATACAGTCACTTAATTCCTTGGCCTTA |
hsa_circ_0033389 | ACTTCATTAGAGGGGTGGTAGACTCGGAGGATCTCCCTCTAAACATATCCCGTGAGATGTTGCAACAAAGCAAAATTTTGAAAGTTATCAGGAAGAATTTGGTCAAAAAATGCTTAGAACTCTTTACTGAACTGGCGGAAGATAAAGAGAACTACAAGAAATTCTATGAGCAGTTCTCTAAAAACATAAAGCTTGGAATACACGAAGACTCTCAAAATCGGAAGAAGCTTTCAGAGCTGTTAAGGTACTACACATCTGCCTCTGGTGATGAGATGGTTTCTCTCAAGGACTACTGCACCAGAATGAAGGAGAACCAGAAACATATCTATTATATCACAGGTGAGACCAAGGACCAGGTAGCTAACTCAGCCTTTGTGGAACGTCTTCGGAAACATGGCTTAGAAGTGATCTATATGATTGAGCCCATTGATGAGTACTGTGTCCAACAGCTGAAGGAATTTGAGGGGAAGACTTTAGTGTCAGTCACCAAAGAAGGCCTGGAACTTCCAGAGGATGAAGAAGAGAAAAAGAAGCAGGAAGAGAAAAAAACAAAGTTTGAGAACCTCTGCAAAATCATGAAAGACATATTGGAGAAAAAAGTTGAAAAGGTGGTTGTGTCAAACCGATTGGTGACATCTCCATGCTGTATTGTCACAAGCACATATGGCTGGACAGCAAACATGGAGAGAATCATGAAAGCTCAAGCCCTAAGAGACAACTCAACAATGGGTTACATGGCAGCAAAGAAACACCTGGAGATAAACCCTGACCATTCCATTATTGAGACCTTAAGGCAAAAGGCAGAGGCTGATAAGAACGACAAGTCTGTGAAGGATCTGGTCATCTTGCTTTATGAAACTGCGCTCCTGTCTTCTGGCTTCAGTCTGGAAGATCCCCAGACACATGCTAACAGGATCTACAGGATGATCAAACTTGGTCTGGGTATTGATGAAGATGACCCTACTGCTGATGATACCAGTGCTGCTGTAACTGAAGAAATGCCACCCCTTGAAGGAGATGACGACACATCACGCATGGAAGAAGTAGACTAATCTCTGGCTGAGGGATGACTTACCTGTTCAGTACTCTACAATTCCTCTGATAATATATTTTCAAGGATGTTTTTCTTTATTTTTGTTAATATTAAAAAGTCTGTATGGCATGACAACTACTTTAAGGGGAAGATAAGATTTCTGTCTACTAAGTGATGCTGTGATACCTTAGGCACTAAAGCAGAGCTAGTAATGCTTTTTGAGTTTCATGTTGGTTTATTTTCACAGATTGGGGTAACGTGCACTGTAAGACGTATGTAACATGATGTTAACTTTGTGGTCTAAAGTGTTTAGCTGTCAAGCCGGATGCCTAAGTAGACCAAATCTTGTTATTGAAGTGTTCTGAGCTGTATCTTGATGTTTAGAAAAGTATTCGTTACATCTTGTAGGATCTACTTTTTGAACTTTTCATTCCCTGTAGTTGACAATTCTGCATGTACTAGTCCTCTAGAAATAGGTTAAACTGAAGCAACTTGATGGAAGGATCTCTCCACAGGGCTTGTTTTCCAAAGAAAAGTATTGTTTGGAGGAGCAAAGTTAAAAGCCTACCTAAGCATATCGTAAAGCTGTTCAAAAATAACTCAGACCCAGTCTTGTGGATGGAAATGTAGTGCTCGAGTCACATTCTGCTTAAAGTTGTAACAAATACAGATGAGTTAAAAGATATTGTGTGACAGTGTCTTATTTAGGGGGAAAGGGGAGTATCTGGATGACAGTTAGTGCCAAAATGTAAAACATGAGGCGCTAGCAGGAGATGGTTAAACACTAGCTGCTCCAAGGGTTGACATGGTCTTCCCAGCATGTACTCAGCAGGTGTGGGGTGGAGCACACGTAGGCACAGAAAACAGGAATGCAGACAACATGCATCCCCTGCGTCCATGAGTTACATGTGTTCTCTTAGTGTCCACGTTGTTTTGATGTTATTCATGGAATACCTTCTGTGTTAAATACAGTCACTTAATTCCTTGGCCTTA |
hsa_circ_0033390 | CATTTTTCAGTTGAAGGACAGTTGGAATTCAGAGCCCTTCTATTTGTCCCACGACGTGCTCCTTTTGATCTGTTTGAAAACAGAAAGAAAAAGAACAACATCAAATTGTATGTACGCAGAGTTTTCATCATGGATAACTGTGAGGAGCTAATCCCTGAATATCTGAACTTCATTAGAGGGGTGGTAGACTCGGAGGATCTCCCTCTAAACATATCCCGTGAGATGTTGCAACAAAGCAAAATTTTGAAAGTTATCAGGAAGAATTTGGTCAAAAAATGCTTAGAACTCTTTACTGAACTGGCGGAAGATAAAGAGAACTACAAGAAATTCTATGAGCAGTTCTCTAAAAACATAAAGCTTGGAATACACGAAGACTCTCAAAATCGGAAGAAGCTTTCAGAGCTGTTAAGGTACTACACATCTGCCTCTGGTGATGAGATGGTTTCTCTCAAGGACTACTGCACCAGAATGAAGGAGAACCAGAAACATATCTATTATATCACAGGTGAGACCAAGGACCAGGTAGCTAACTCAGCCTTTGTGGAACGTCTTCGGAAACATGGCTTAGAAGTGATCTATATGATTGAGCCCATTGATGAGTACTGTGTCCAACAGCTGAAGGAATTTGAGGGGAAGACTTTAGTGTCAGTCACCAAAGAAGGCCTGGAACTTCCAGAGGATGAAGAAGAGAAAAAGAAGCAGGAAGAGAAAAAAACAAAGTTTGAGAACCTCTGCAAAATCATGAAAGACATATTGGAGAAAAAAGTTGAAAAGGTGGTTGTGTCAAACCGATTGGTGACATCTCCATGCTGTATTGTCACAAGCACATATGGCTGGACAGCAAACATGGAGAGAATCATGAAAGCTCAAGCCCTAAGAGACAACTCAACAATGGGTTACATGGCAGCAAAGAAACACCTGGAGATAAACCCTGACCATTCCATTATTGAGACCTTAAGGCAAAAGGCAGAGGCTGATAAGAACGACAAGTCTGTGAAGGATCTGGTCATCTTGCTTTATGAAACTGCGCTCCTGTCTTCTGGCTTCAGTCTGGAAGATCCCCAGACACATGCTAACAGGATCTACAGGATGATCAAACTTGGTCTGGGTATTGATGAAGATGACCCTACTGCTGATGATACCAGTGCTGCTGTAACTGAAGAAATGCCACCCCTTGAAGGAGATGACGACACATCACGCATGGAAGAAGTAGACTAATCTCTGGCTGAGGGATGACTTACCTGTTCAGTACTCTACAATTCCTCTGATAATATATTTTCAAGGATGTTTTTCTTTATTTTTGTTAATATTAAAAAGTCTGTATGGCATGACAACTACTTTAAGGGGAAGATAAGATTTCTGTCTACTAAGTGATGCTGTGATACCTTAGGCACTAAAGCAGAGCTAGTAATGCTTTTTGAGTTTCATGTTGGTTTATTTTCACAGATTGGGGTAACGTGCACTGTAAGACGTATGTAACATGATGTTAACTTTGTGGTCTAAAGTGTTTAGCTGTCAAGCCGGATGCCTAAGTAGACCAAATCTTGTTATTGAAGTGTTCTGAGCTGTATCTTGATGTTTAGAAAAGTATTCGTTACATCTTGTAGGATCTACTTTTTGAACTTTTCATTCCCTGTAGTTGACAATTCTGCATGTACTAGTCCTCTAGAAATAGGTTAAACTGAAGCAACTTGATGGAAGGATCTCTCCACAGGGCTTGTTTTCCAAAGAAAAGTATTGTTTGGAGGAGCAAAGTTAAAAGCCTACCTAAGCATATCGTAAAGCTGTTCAAAAATAACTCAGACCCAGTCTTGTGGATGGAAATGTAGTGCTCGAGTCACATTCTGCTTAAAGTTGTAACAAATACAGATGAGTTAAAAGATATTGTGTGACAGTGTCTTATTTAGGGGGAAAGGGGAGTATCTGGATGACAGTTAGTGCCAAAATGTAAAACATGAGGCGCTAGCAGGAGATGGTTAAACACTAGCTGCTCCAAGGGTTGACATGGTCTTCCCAGCATGTACTCAGCAGGTGTGGGGTGGAGCACACGTAGGCACAGAAAACAGGAATGCAGACAACATGCATCCCCTGCGTCCATGAGTTACATGTGTTCTCTTAGTGTCCACGTTGTTTTGATGTTATTCATGGAATACCTTCTGTGTTAAATACAGTCACTTAATTCCTTGGCCTTA |
hsa_circ_0033391 | GTGGAGAAGGAACGTGATAAAGAAGTAAGCGATGATGAGGCTGAAGAAAAGGAAGACAAAGAAGAAGAAAAAGAAAAAGAAGAGAAAGAGTCGGAAGACAAACCTGAAATTGAAGATGTTGGTTCTGATGAGGAAGAAGAAAAGAAGGATGGTGACAAGAAGAAGAAGAAGAAGATTAAGGAAAAGTACATCGATCAAGAAGAGCTCAACAAAACAAAGCCCATCTGGACCAGAAATCCCGACGATATTACTAATGAGGAGTACGGAGAATTCTATAAGAGCTTGACCAATGACTGGGAAGATCACTTGGCAGTGAAGCATTTTTCAGTTGAAGGACAGTTGGAATTCAGAGCCCTTCTATTTGTCCCACGACGTGCTCCTTTTGATCTGTTTGAAAACAGAAAGAAAAAGAACAACATCAAATTGTATGTACGCAGAGTTTTCATCATGGATAACTGTGAGGAGCTAATCCCTGAATATCTGAACTTCATTAGAGGGGTGGTAGACTCGGAGGATCTCCCTCTAAACATATCCCGTGAGATGTTGCAACAAAGCAAAATTTTGAAAGTTATCAGGAAGAATTTGGTCAAAAAATGCTTAGAACTCTTTACTGAACTGGCGGAAGATAAAGAGAACTACAAGAAATTCTATGAGCAGTTCTCTAAAAACATAAAGCTTGGAATACACGAAGACTCTCAAAATCGGAAGAAGCTTTCAGAGCTGTTAAGGTACTACACATCTGCCTCTGGTGATGAGATGGTTTCTCTCAAGGACTACTGCACCAGAATGAAGGAGAACCAGAAACATATCTATTATATCACAGGTGAGACCAAGGACCAGGTAGCTAACTCAGCCTTTGTGGAACGTCTTCGGAAACATGGCTTAGAAGTGATCTATATGATTGAGCCCATTGATGAGTACTGTGTCCAACAGCTGAAGGAATTTGAGGGGAAGACTTTAGTGTCAGTCACCAAAGAAGGCCTGGAACTTCCAGAGGATGAAGAAGAGAAAAAGAAGCAGGAAGAGAAAAAAACAAAGTTTGAGAACCTCTGCAAAATCATGAAAGACATATTGGAGAAAAAAGTTGAAAAGGTGGTTGTGTCAAACCGATTGGTGACATCTCCATGCTGTATTGTCACAAGCACATATGGCTGGACAGCAAACATGGAGAGAATCATGAAAGCTCAAGCCCTAAGAGACAACTCAACAATGGGTTACATGGCAGCAAAGAAACACCTGGAGATAAACCCTGACCATTCCATTATTGAGACCTTAAGGCAAAAGGCAGAGGCTGATAAGAACGACAAGTCTGTGAAGGATCTGGTCATCTTGCTTTATGAAACTGCGCTCCTGTCTTCTGGCTTCAGTCTGGAAGATCCCCAGACACATGCTAACAGGATCTACAGGATGATCAAACTTGGTCTGGGTATTGATGAAGATGACCCTACTGCTGATGATACCAGTGCTGCTGTAACTGAAGAAATGCCACCCCTTGAAGGAGATGACGACACATCACGCATGGAAGAAGTAGACTAATCTCTGGCTGAGGGATGACTTACCTGTTCAGTACTCTACAATTCCTCTGATAATATATTTTCAAGGATGTTTTTCTTTATTTTTGTTAATATTAAAAAGTCTGTATGGCATGACAACTACTTTAAGGGGAAGATAAGATTTCTGTCTACTAAGTGATGCTGTGATACCTTAGGCACTAAAGCAGAGCTAGTAATGCTTTTTGAGTTTCATGTTGGTTTATTTTCACAGATTGGGGTAACGTGCACTGTAAGACGTATGTAACATGATGTTAACTTTGTGGTCTAAAGTGTTTAGCTGTCAAGCCGGATGCCTAAGTAGACCAAATCTTGTTATTGAAGTGTTCTGAGCTGTATCTTGATGTTTAGAAAAGTATTCGTTACATCTTGTAGGATCTACTTTTTGAACTTTTCATTCCCTGTAGTTGACAATTCTGCATGTACTAGTCCTCTAGAAATAGGTTAAACTGAAGCAACTTGATGGAAGGATCTCTCCACAGGGCTTGTTTTCCAAAGAAAAGTATTGTTTGGAGGAGCAAAGTTAAAAGCCTACCTAAGCATATCGTAAAGCTGTTCAAAAATAACTCAGACCCAGTCTTGTGGATGGAAATGTAGTGCTCGAGTCACATTCTGCTTAAAGTTGTAACAAATACAGATGAGTTAAAAGATATTGTGTGACAGTGTCTTATTTAGGGGGAAAGGGGAGTATCTGGATGACAGTTAGTGCCAAAATGTAAAACATGAGGCGCTAGCAGGAGATGGTTAAACACTAGCTGCTCCAAGGGTTGACATGGTCTTCCCAGCATGTACTCAGCAGGTGTGGGGTGGAGCACACGTAGGCACAGAAAACAGGAATGCAGACAACATGCATCCCCTGCGTCCATGAGTTACATGTGTTCTCTTAGTGTCCACGTTGTTTTGATGTTATTCATGGAATACCTTCTGTGTTAAATACAGTCACTTAATTCCTTGGCCTTA |
hsa_circ_0033392 | GTGAACCTATGGGTCGTGGAACAAAAGTTATCCTACACCTGAAAGAAGACCAAACTGAGTACTTGGAGGAACGAAGAATAAAGGAGATTGTGAAGAAACATTCTCAGTTTATTGGATATCCCATTACTCTTTTTGTGGAGAAGGAACGTGATAAAGAAGTAAGCGATGATGAGGCTGAAGAAAAGGAAGACAAAGAAGAAGAAAAAGAAAAAGAAGAGAAAGAGTCGGAAGACAAACCTGAAATTGAAGATGTTGGTTCTGATGAGGAAGAAGAAAAGAAGGATGGTGACAAGAAGAAGAAGAAGAAGATTAAGGAAAAGTACATCGATCAAGAAGAGCTCAACAAAACAAAGCCCATCTGGACCAGAAATCCCGACGATATTACTAATGAGGAGTACGGAGAATTCTATAAGAGCTTGACCAATGACTGGGAAGATCACTTGGCAGTGAAGCATTTTTCAGTTGAAGGACAGTTGGAATTCAGAGCCCTTCTATTTGTCCCACGACGTGCTCCTTTTGATCTGTTTGAAAACAGAAAGAAAAAGAACAACATCAAATTGTATGTACGCAGAGTTTTCATCATGGATAACTGTGAGGAGCTAATCCCTGAATATCTGAACTTCATTAGAGGGGTGGTAGACTCGGAGGATCTCCCTCTAAACATATCCCGTGAGATGTTGCAACAAAGCAAAATTTTGAAAGTTATCAGGAAGAATTTGGTCAAAAAATGCTTAGAACTCTTTACTGAACTGGCGGAAGATAAAGAGAACTACAAGAAATTCTATGAGCAGTTCTCTAAAAACATAAAGCTTGGAATACACGAAGACTCTCAAAATCGGAAGAAGCTTTCAGAGCTGTTAAGGTACTACACATCTGCCTCTGGTGATGAGATGGTTTCTCTCAAGGACTACTGCACCAGAATGAAGGAGAACCAGAAACATATCTATTATATCACAGGTGAGACCAAGGACCAGGTAGCTAACTCAGCCTTTGTGGAACGTCTTCGGAAACATGGCTTAGAAGTGATCTATATGATTGAGCCCATTGATGAGTACTGTGTCCAACAGCTGAAGGAATTTGAGGGGAAGACTTTAGTGTCAGTCACCAAAGAAGGCCTGGAACTTCCAGAGGATGAAGAAGAGAAAAAGAAGCAGGAAGAGAAAAAAACAAAGTTTGAGAACCTCTGCAAAATCATGAAAGACATATTGGAGAAAAAAGTTGAAAAGGTGGTTGTGTCAAACCGATTGGTGACATCTCCATGCTGTATTGTCACAAGCACATATGGCTGGACAGCAAACATGGAGAGAATCATGAAAGCTCAAGCCCTAAGAGACAACTCAACAATGGGTTACATGGCAGCAAAGAAACACCTGGAGATAAACCCTGACCATTCCATTATTGAGACCTTAAGGCAAAAGGCAGAGGCTGATAAGAACGACAAGTCTGTGAAGGATCTGGTCATCTTGCTTTATGAAACTGCGCTCCTGTCTTCTGGCTTCAGTCTGGAAGATCCCCAGACACATGCTAACAGGATCTACAGGATGATCAAACTTGGTCTGGGTATTGATGAAGATGACCCTACTGCTGATGATACCAGTGCTGCTGTAACTGAAGAAATGCCACCCCTTGAAGGAGATGACGACACATCACGCATGGAAGAAGTAGACTAATCTCTGGCTGAGGGATGACTTACCTGTTCAGTACTCTACAATTCCTCTGATAATATATTTTCAAGGATGTTTTTCTTTATTTTTGTTAATATTAAAAAGTCTGTATGGCATGACAACTACTTTAAGGGGAAGATAAGATTTCTGTCTACTAAGTGATGCTGTGATACCTTAGGCACTAAAGCAGAGCTAGTAATGCTTTTTGAGTTTCATGTTGGTTTATTTTCACAGATTGGGGTAACGTGCACTGTAAGACGTATGTAACATGATGTTAACTTTGTGGTCTAAAGTGTTTAGCTGTCAAGCCGGATGCCTAAGTAGACCAAATCTTGTTATTGAAGTGTTCTGAGCTGTATCTTGATGTTTAGAAAAGTATTCGTTACATCTTGTAGGATCTACTTTTTGAACTTTTCATTCCCTGTAGTTGACAATTCTGCATGTACTAGTCCTCTAGAAATAGGTTAAACTGAAGCAACTTGATGGAAGGATCTCTCCACAGGGCTTGTTTTCCAAAGAAAAGTATTGTTTGGAGGAGCAAAGTTAAAAGCCTACCTAAGCATATCGTAAAGCTGTTCAAAAATAACTCAGACCCAGTCTTGTGGATGGAAATGTAGTGCTCGAGTCACATTCTGCTTAAAGTTGTAACAAATACAGATGAGTTAAAAGATATTGTGTGACAGTGTCTTATTTAGGGGGAAAGGGGAGTATCTGGATGACAGTTAGTGCCAAAATGTAAAACATGAGGCGCTAGCAGGAGATGGTTAAACACTAGCTGCTCCAAGGGTTGACATGGTCTTCCCAGCATGTACTCAGCAGGTGTGGGGTGGAGCACACGTAGGCACAGAAAACAGGAATGCAGACAACATGCATCCCCTGCGTCCATGAGTTACATGTGTTCTCTTAGTGTCCACGTTGTTTTGATGTTATTCATGGAATACCTTCTGTGTTAAATACAGTCACTTAATTCCTTGGCCTTA |
hsa_circ_0033393 | GCATTGGACAAAATCCGGTATGAAAGCTTGACAGATCCCAGTAAATTAGACTCTGGGAAAGAGCTGCATATTAACCTTATACCGAACAAACAAGATCGAACTCTCACTATTGTGGATACTGGAATTGGAATGACCAAGGCTGACTTGATCAATAACCTTGGTACTATCGCCAAGTCTGGGACCAAAGCGTTCATGGAAGCTTTGCAGGCTGGTGCAGATATCTCTATGATTGGCCAGTTCGGTGTTGGTTTTTATTCTGCTTATTTGGTTGCTGAGAAAGTAACTGTGATCACCAAACATAACGATGATGAGCAGTACGCTTGGGAGTCCTCAGCAGGGGGATCATTCACAGTGAGGACAGACACAGGTGAACCTATGGGTCGTGGAACAAAAGTTATCCTACACCTGAAAGAAGACCAAACTGAGTACTTGGAGGAACGAAGAATAAAGGAGATTGTGAAGAAACATTCTCAGTTTATTGGATATCCCATTACTCTTTTTGTGGAGAAGGAACGTGATAAAGAAGTAAGCGATGATGAGGCTGAAGAAAAGGAAGACAAAGAAGAAGAAAAAGAAAAAGAAGAGAAAGAGTCGGAAGACAAACCTGAAATTGAAGATGTTGGTTCTGATGAGGAAGAAGAAAAGAAGGATGGTGACAAGAAGAAGAAGAAGAAGATTAAGGAAAAGTACATCGATCAAGAAGAGCTCAACAAAACAAAGCCCATCTGGACCAGAAATCCCGACGATATTACTAATGAGGAGTACGGAGAATTCTATAAGAGCTTGACCAATGACTGGGAAGATCACTTGGCAGTGAAGCATTTTTCAGTTGAAGGACAGTTGGAATTCAGAGCCCTTCTATTTGTCCCACGACGTGCTCCTTTTGATCTGTTTGAAAACAGAAAGAAAAAGAACAACATCAAATTGTATGTACGCAGAGTTTTCATCATGGATAACTGTGAGGAGCTAATCCCTGAATATCTGAACTTCATTAGAGGGGTGGTAGACTCGGAGGATCTCCCTCTAAACATATCCCGTGAGATGTTGCAACAAAGCAAAATTTTGAAAGTTATCAGGAAGAATTTGGTCAAAAAATGCTTAGAACTCTTTACTGAACTGGCGGAAGATAAAGAGAACTACAAGAAATTCTATGAGCAGTTCTCTAAAAACATAAAGCTTGGAATACACGAAGACTCTCAAAATCGGAAGAAGCTTTCAGAGCTGTTAAGGTACTACACATCTGCCTCTGGTGATGAGATGGTTTCTCTCAAGGACTACTGCACCAGAATGAAGGAGAACCAGAAACATATCTATTATATCACAGGTGAGACCAAGGACCAGGTAGCTAACTCAGCCTTTGTGGAACGTCTTCGGAAACATGGCTTAGAAGTGATCTATATGATTGAGCCCATTGATGAGTACTGTGTCCAACAGCTGAAGGAATTTGAGGGGAAGACTTTAGTGTCAGTCACCAAAGAAGGCCTGGAACTTCCAGAGGATGAAGAAGAGAAAAAGAAGCAGGAAGAGAAAAAAACAAAGTTTGAGAACCTCTGCAAAATCATGAAAGACATATTGGAGAAAAAAGTTGAAAAGGTGGTTGTGTCAAACCGATTGGTGACATCTCCATGCTGTATTGTCACAAGCACATATGGCTGGACAGCAAACATGGAGAGAATCATGAAAGCTCAAGCCCTAAGAGACAACTCAACAATGGGTTACATGGCAGCAAAGAAACACCTGGAGATAAACCCTGACCATTCCATTATTGAGACCTTAAGGCAAAAGGCAGAGGCTGATAAGAACGACAAGTCTGTGAAGGATCTGGTCATCTTGCTTTATGAAACTGCGCTCCTGTCTTCTGGCTTCAGTCTGGAAGATCCCCAGACACATGCTAACAGGATCTACAGGATGATCAAACTTGGTCTGGGTATTGATGAAGATGACCCTACTGCTGATGATACCAGTGCTGCTGTAACTGAAGAAATGCCACCCCTTGAAGGAGATGACGACACATCACGCATGGAAGAAGTAGACTAATCTCTGGCTGAGGGATGACTTACCTGTTCAGTACTCTACAATTCCTCTGATAATATATTTTCAAGGATGTTTTTCTTTATTTTTGTTAATATTAAAAAGTCTGTATGGCATGACAACTACTTTAAGGGGAAGATAAGATTTCTGTCTACTAAGTGATGCTGTGATACCTTAGGCACTAAAGCAGAGCTAGTAATGCTTTTTGAGTTTCATGTTGGTTTATTTTCACAGATTGGGGTAACGTGCACTGTAAGACGTATGTAACATGATGTTAACTTTGTGGTCTAAAGTGTTTAGCTGTCAAGCCGGATGCCTAAGTAGACCAAATCTTGTTATTGAAGTGTTCTGAGCTGTATCTTGATGTTTAGAAAAGTATTCGTTACATCTTGTAGGATCTACTTTTTGAACTTTTCATTCCCTGTAGTTGACAATTCTGCATGTACTAGTCCTCTAGAAATAGGTTAAACTGAAGCAACTTGATGGAAGGATCTCTCCACAGGGCTTGTTTTCCAAAGAAAAGTATTGTTTGGAGGAGCAAAGTTAAAAGCCTACCTAAGCATATCGTAAAGCTGTTCAAAAATAACTCAGACCCAGTCTTGTGGATGGAAATGTAGTGCTCGAGTCACATTCTGCTTAAAGTTGTAACAAATACAGATGAGTTAAAAGATATTGTGTGACAGTGTCTTATTTAGGGGGAAAGGGGAGTATCTGGATGACAGTTAGTGCCAAAATGTAAAACATGAGGCGCTAGCAGGAGATGGTTAAACACTAGCTGCTCCAAGGGTTGACATGGTCTTCCCAGCATGTACTCAGCAGGTGTGGGGTGGAGCACACGTAGGCACAGAAAACAGGAATGCAGACAACATGCATCCCCTGCGTCCATGAGTTACATGTGTTCTCTTAGTGTCCACGTTGTTTTGATGTTATTCATGGAATACCTTCTGTGTTAAATACAGTCACTTAATTCCTTGGCCTTA |
hsa_circ_0033394 | ATGCCTGAGGAAACCCAGACCCAAGACCAACCGATGGAGGAGGAGGAGGTTGAGACGTTCGCCTTTCAGGCAGAAATTGCCCAGTTGATGTCATTGATCATCAATACTTTCTACTCGAACAAAGAGATCTTTCTGAGAGAGCTCATTTCAAATTCATCAGATGCATTGGACAAAATCCGGTATGAAAGCTTGACAGATCCCAGTAAATTAGACTCTGGGAAAGAGCTGCATATTAACCTTATACCGAACAAACAAGATCGAACTCTCACTATTGTGGATACTGGAATTGGAATGACCAAGGCTGACTTGATCAATAACCTTGGTACTATCGCCAAGTCTGGGACCAAAGCGTTCATGGAAGCTTTGCAGGCTGGTGCAGATATCTCTATGATTGGCCAGTTCGGTGTTGGTTTTTATTCTGCTTATTTGGTTGCTGAGAAAGTAACTGTGATCACCAAACATAACGATGATGAGCAGTACGCTTGGGAGTCCTCAGCAGGGGGATCATTCACAGTGAGGACAGACACAGGTGAACCTATGGGTCGTGGAACAAAAGTTATCCTACACCTGAAAGAAGACCAAACTGAGTACTTGGAGGAACGAAGAATAAAGGAGATTGTGAAGAAACATTCTCAGTTTATTGGATATCCCATTACTCTTTTTGTGGAGAAGGAACGTGATAAAGAAGTAAGCGATGATGAGGCTGAAGAAAAGGAAGACAAAGAAGAAGAAAAAGAAAAAGAAGAGAAAGAGTCGGAAGACAAACCTGAAATTGAAGATGTTGGTTCTGATGAGGAAGAAGAAAAGAAGGATGGTGACAAGAAGAAGAAGAAGAAGATTAAGGAAAAGTACATCGATCAAGAAGAGCTCAACAAAACAAAGCCCATCTGGACCAGAAATCCCGACGATATTACTAATGAGGAGTACGGAGAATTCTATAAGAGCTTGACCAATGACTGGGAAGATCACTTGGCAGTGAAGCATTTTTCAGTTGAAGGACAGTTGGAATTCAGAGCCCTTCTATTTGTCCCACGACGTGCTCCTTTTGATCTGTTTGAAAACAGAAAGAAAAAGAACAACATCAAATTGTATGTACGCAGAGTTTTCATCATGGATAACTGTGAGGAGCTAATCCCTGAATATCTGAACTTCATTAGAGGGGTGGTAGACTCGGAGGATCTCCCTCTAAACATATCCCGTGAGATGTTGCAACAAAGCAAAATTTTGAAAGTTATCAGGAAGAATTTGGTCAAAAAATGCTTAGAACTCTTTACTGAACTGGCGGAAGATAAAGAGAACTACAAGAAATTCTATGAGCAGTTCTCTAAAAACATAAAGCTTGGAATACACGAAGACTCTCAAAATCGGAAGAAGCTTTCAGAGCTGTTAAGGTACTACACATCTGCCTCTGGTGATGAGATGGTTTCTCTCAAGGACTACTGCACCAGAATGAAGGAGAACCAGAAACATATCTATTATATCACAGGTGAGACCAAGGACCAGGTAGCTAACTCAGCCTTTGTGGAACGTCTTCGGAAACATGGCTTAGAAGTGATCTATATGATTGAGCCCATTGATGAGTACTGTGTCCAACAGCTGAAGGAATTTGAGGGGAAGACTTTAGTGTCAGTCACCAAAGAAGGCCTGGAACTTCCAGAGGATGAAGAAGAGAAAAAGAAGCAGGAAGAGAAAAAAACAAAGTTTGAGAACCTCTGCAAAATCATGAAAGACATATTGGAGAAAAAAGTTGAAAAGGTGGTTGTGTCAAACCGATTGGTGACATCTCCATGCTGTATTGTCACAAGCACATATGGCTGGACAGCAAACATGGAGAGAATCATGAAAGCTCAAGCCCTAAGAGACAACTCAACAATGGGTTACATGGCAGCAAAGAAACACCTGGAGATAAACCCTGACCATTCCATTATTGAGACCTTAAGGCAAAAGGCAGAGGCTGATAAGAACGACAAGTCTGTGAAGGATCTGGTCATCTTGCTTTATGAAACTGCGCTCCTGTCTTCTGGCTTCAGTCTGGAAGATCCCCAGACACATGCTAACAGGATCTACAGGATGATCAAACTTGGTCTGGGTATTGATGAAGATGACCCTACTGCTGATGATACCAGTGCTGCTGTAACTGAAGAAATGCCACCCCTTGAAGGAGATGACGACACATCACGCATGGAAGAAGTAGACTAATCTCTGGCTGAGGGATGACTTACCTGTTCAGTACTCTACAATTCCTCTGATAATATATTTTCAAGGATGTTTTTCTTTATTTTTGTTAATATTAAAAAGTCTGTATGGCATGACAACTACTTTAAGGGGAAGATAAGATTTCTGTCTACTAAGTGATGCTGTGATACCTTAGGCACTAAAGCAGAGCTAGTAATGCTTTTTGAGTTTCATGTTGGTTTATTTTCACAGATTGGGGTAACGTGCACTGTAAGACGTATGTAACATGATGTTAACTTTGTGGTCTAAAGTGTTTAGCTGTCAAGCCGGATGCCTAAGTAGACCAAATCTTGTTATTGAAGTGTTCTGAGCTGTATCTTGATGTTTAGAAAAGTATTCGTTACATCTTGTAGGATCTACTTTTTGAACTTTTCATTCCCTGTAGTTGACAATTCTGCATGTACTAGTCCTCTAGAAATAGGTTAAACTGAAGCAACTTGATGGAAGGATCTCTCCACAGGGCTTGTTTTCCAAAGAAAAGTATTGTTTGGAGGAGCAAAGTTAAAAGCCTACCTAAGCATATCGTAAAGCTGTTCAAAAATAACTCAGACCCAGTCTTGTGGATGGAAATGTAGTGCTCGAGTCACATTCTGCTTAAAGTTGTAACAAATACAGATGAGTTAAAAGATATTGTGTGACAGTGTCTTATTTAGGGGGAAAGGGGAGTATCTGGATGACAGTTAGTGCCAAAATGTAAAACATGAGGCGCTAGCAGGAGATGGTTAAACACTAGCTGCTCCAAGGGTTGACATGGTCTTCCCAGCATGTACTCAGCAGGTGTGGGGTGGAGCACACGTAGGCACAGAAAACAGGAATGCAGACAACATGCATCCCCTGCGTCCATGAGTTACATGTGTTCTCTTAGTGTCCACGTTGTTTTGATGTTATTCATGGAATACCTTCTGTGTTAAATACAGTCACTTAATTCCTTGGCCTTA |
hsa_circ_0033395 | GCATGCGTAGGCGCGCGGCCGCGGCGGCGGCTGGGGAGGGTTCTTCCGGAAGGTTCGGGAGGCTTCTGGAAAAAGCGCCGCGCGCTGGGCGGGCCCGTCGCTATATAAGGCAGGCGCGGGGGTGGCGCGTCAGTTGCTTCAGCGTCCCGGTGTGGCTGTGCCGTTGGTCCTGTGCGGTCACTTAGCCAAGATGCCTGAGGAAACCCAGACCCAAGACCAACCGATGGAGGAGGAGGAGGTTGAGACGTTCGCCTTTCAGGCAGAAATTGCCCAGTTGATGTCATTGATCATCAATACTTTCTACTCGAACAAAGAGATCTTTCTGAGAGAGCTCATTTCAAATTCATCAGATGCATTGGACAAAATCCGGTATGAAAGCTTGACAGATCCCAGTAAATTAGACTCTGGGAAAGAGCTGCATATTAACCTTATACCGAACAAACAAGATCGAACTCTCACTATTGTGGATACTGGAATTGGAATGACCAAGGCTGACTTGATCAATAACCTTGGTACTATCGCCAAGTCTGGGACCAAAGCGTTCATGGAAGCTTTGCAGGCTGGTGCAGATATCTCTATGATTGGCCAGTTCGGTGTTGGTTTTTATTCTGCTTATTTGGTTGCTGAGAAAGTAACTGTGATCACCAAACATAACGATGATGAGCAGTACGCTTGGGAGTCCTCAGCAGGGGGATCATTCACAGTGAGGACAGACACAGGTGAACCTATGGGTCGTGGAACAAAAGTTATCCTACACCTGAAAGAAGACCAAACTGAGTACTTGGAGGAACGAAGAATAAAGGAGATTGTGAAGAAACATTCTCAGTTTATTGGATATCCCATTACTCTTTTTGTGGAGAAGGAACGTGATAAAGAAGTAAGCGATGATGAGGCTGAAGAAAAGGAAGACAAAGAAGAAGAAAAAGAAAAAGAAGAGAAAGAGTCGGAAGACAAACCTGAAATTGAAGATGTTGGTTCTGATGAGGAAGAAGAAAAGAAGGATGGTGACAAGAAGAAGAAGAAGAAGATTAAGGAAAAGTACATCGATCAAGAAGAGCTCAACAAAACAAAGCCCATCTGGACCAGAAATCCCGACGATATTACTAATGAGGAGTACGGAGAATTCTATAAGAGCTTGACCAATGACTGGGAAGATCACTTGGCAGTGAAGCATTTTTCAGTTGAAGGACAGTTGGAATTCAGAGCCCTTCTATTTGTCCCACGACGTGCTCCTTTTGATCTGTTTGAAAACAGAAAGAAAAAGAACAACATCAAATTGTATGTACGCAGAGTTTTCATCATGGATAACTGTGAGGAGCTAATCCCTGAATATCTGAACTTCATTAGAGGGGTGGTAGACTCGGAGGATCTCCCTCTAAACATATCCCGTGAGATGTTGCAACAAAGCAAAATTTTGAAAGTTATCAGGAAGAATTTGGTCAAAAAATGCTTAGAACTCTTTACTGAACTGGCGGAAGATAAAGAGAACTACAAGAAATTCTATGAGCAGTTCTCTAAAAACATAAAGCTTGGAATACACGAAGACTCTCAAAATCGGAAGAAGCTTTCAGAGCTGTTAAGGTACTACACATCTGCCTCTGGTGATGAGATGGTTTCTCTCAAGGACTACTGCACCAGAATGAAGGAGAACCAGAAACATATCTATTATATCACAGGTGAGACCAAGGACCAGGTAGCTAACTCAGCCTTTGTGGAACGTCTTCGGAAACATGGCTTAGAAGTGATCTATATGATTGAGCCCATTGATGAGTACTGTGTCCAACAGCTGAAGGAATTTGAGGGGAAGACTTTAGTGTCAGTCACCAAAGAAGGCCTGGAACTTCCAGAGGATGAAGAAGAGAAAAAGAAGCAGGAAGAGAAAAAAACAAAGTTTGAGAACCTCTGCAAAATCATGAAAGACATATTGGAGAAAAAAGTTGAAAAGGTGGTTGTGTCAAACCGATTGGTGACATCTCCATGCTGTATTGTCACAAGCACATATGGCTGGACAGCAAACATGGAGAGAATCATGAAAGCTCAAGCCCTAAGAGACAACTCAACAATGGGTTACATGGCAGCAAAGAAACACCTGGAGATAAACCCTGACCATTCCATTATTGAGACCTTAAGGCAAAAGGCAGAGGCTGATAAGAACGACAAGTCTGTGAAGGATCTGGTCATCTTGCTTTATGAAACTGCGCTCCTGTCTTCTGGCTTCAGTCTGGAAGATCCCCAGACACATGCTAACAGGATCTACAGGATGATCAAACTTGGTCTGGGTATTGATGAAGATGACCCTACTGCTGATGATACCAGTGCTGCTGTAACTGAAGAAATGCCACCCCTTGAAGGAGATGACGACACATCACGCATGGAAGAAGTAGACTAATCTCTGGCTGAGGGATGACTTACCTGTTCAGTACTCTACAATTCCTCTGATAATATATTTTCAAGGATGTTTTTCTTTATTTTTGTTAATATTAAAAAGTCTGTATGGCATGACAACTACTTTAAGGGGAAGATAAGATTTCTGTCTACTAAGTGATGCTGTGATACCTTAGGCACTAAAGCAGAGCTAGTAATGCTTTTTGAGTTTCATGTTGGTTTATTTTCACAGATTGGGGTAACGTGCACTGTAAGACGTATGTAACATGATGTTAACTTTGTGGTCTAAAGTGTTTAGCTGTCAAGCCGGATGCCTAAGTAGACCAAATCTTGTTATTGAAGTGTTCTGAGCTGTATCTTGATGTTTAGAAAAGTATTCGTTACATCTTGTAGGATCTACTTTTTGAACTTTTCATTCCCTGTAGTTGACAATTCTGCATGTACTAGTCCTCTAGAAATAGGTTAAACTGAAGCAACTTGATGGAAGGATCTCTCCACAGGGCTTGTTTTCCAAAGAAAAGTATTGTTTGGAGGAGCAAAGTTAAAAGCCTACCTAAGCATATCGTAAAGCTGTTCAAAAATAACTCAGACCCAGTCTTGTGGATGGAAATGTAGTGCTCGAGTCACATTCTGCTTAAAGTTGTAACAAATACAGATGAGTTAAAAGATATTGTGTGACAGTGTCTTATTTAGGGGGAAAGGGGAGTATCTGGATGACAGTTAGTGCCAAAATGTAAAACATGAGGCGCTAGCAGGAGATGGTTAAACACTAGCTGCTCCAAGGGTTGACATGGTCTTCCCAGCATGTACTCAGCAGGTGTGGGGTGGAGCACACGTAGGCACAGAAAACAGGAATGCAGACAACATGCATCCCCTGCGTCCATGAGTTACATGTGTTCTCTTAGTGTCCACGTTGTTTTGATGTTATTCATGGAATACCTTCTGTGTTAAATACAGTCACTTAATTCCTTGGCCTTA |
hsa_circ_0033396 | GACTGCGCAGGCGTGCTCACCTGGCGTGCTCCACCCGACTGGGCGTCCGCAGGCTCCTCCCCCGGGTGTGGCCTCCGGGCGGCATGGCTGCTTCCCAGGTGATGCCGGCTTCAGCTAGTGGGGTCTAGTTGACCGTTCCGCAGCCGCCAGGGCCAGCGGAAAGCCGGTCAGGGGGAACCGCGGCGGGGCTGGTGTCATGAGCCTGAGGTGAACTTGAGGGTGCCTCCTCAGCGGTCTCCCGCCCTGCCCTGAGGGGCGCCGGGACCCCAAAGAGCGGAGGAAGAGCGCCACCCCGACGGCCACCGCTTCGGAGCCAGCACGCGGGGTACCCTACGGGGAGCGCGGATGCCCCCGTGTTCGGGCGGGGACGGCTCCACCCCTCCTGGGCCCTCCCTTCGGGACAGGGACTGTCCCGCCCAGAGTGCTGAATACCCGCGCGACCGTCTGGATCCCCGCCCAGGAAGCCCCTCTGAAGCCTCCTCGCCGCCGTTTCTGAGAAGCAGGGCACCTGTTAACTGGTACCAAGAAAAGGCCCAAGTGTTTCTCTGGCATCTGATGGTGTCTGGATCCACCACTCTACTCTGTCTCTGGAAACAGCCCTTCCACGTCTCTGCATTCCCTGTCACCGCGTCACTGGCCTTCAGACAGAGCCAAGGTGCAGGGCAACACCTCTACAAGGATCTGCAGCCATTTATATTGCTTAGGCTACTGATGCCTGAGGAAACCCAGACCCAAGACCAACCGATGGAGGAGGAGGAGGTTGAGACGTTCGCCTTTCAGGCAGAAATTGCCCAGTTGATGTCATTGATCATCAATACTTTCTACTCGAACAAAGAGATCTTTCTGAGAGAGCTCATTTCAAATTCATCAGATGCATTGGACAAAATCCGGTATGAAAGCTTGACAGATCCCAGTAAATTAGACTCTGGGAAAGAGCTGCATATTAACCTTATACCGAACAAACAAGATCGAACTCTCACTATTGTGGATACTGGAATTGGAATGACCAAGGCTGACTTGATCAATAACCTTGGTACTATCGCCAAGTCTGGGACCAAAGCGTTCATGGAAGCTTTGCAGGCTGGTGCAGATATCTCTATGATTGGCCAGTTCGGTGTTGGTTTTTATTCTGCTTATTTGGTTGCTGAGAAAGTAACTGTGATCACCAAACATAACGATGATGAGCAGTACGCTTGGGAGTCCTCAGCAGGGGGATCATTCACAGTGAGGACAGACACAGGTGAACCTATGGGTCGTGGAACAAAAGTTATCCTACACCTGAAAGAAGACCAAACTGAGTACTTGGAGGAACGAAGAATAAAGGAGATTGTGAAGAAACATTCTCAGTTTATTGGATATCCCATTACTCTTTTTGTGGAGAAGGAACGTGATAAAGAAGTAAGCGATGATGAGGCTGAAGAAAAGGAAGACAAAGAAGAAGAAAAAGAAAAAGAAGAGAAAGAGTCGGAAGACAAACCTGAAATTGAAGATGTTGGTTCTGATGAGGAAGAAGAAAAGAAGGATGGTGACAAGAAGAAGAAGAAGAAGATTAAGGAAAAGTACATCGATCAAGAAGAGCTCAACAAAACAAAGCCCATCTGGACCAGAAATCCCGACGATATTACTAATGAGGAGTACGGAGAATTCTATAAGAGCTTGACCAATGACTGGGAAGATCACTTGGCAGTGAAGCATTTTTCAGTTGAAGGACAGTTGGAATTCAGAGCCCTTCTATTTGTCCCACGACGTGCTCCTTTTGATCTGTTTGAAAACAGAAAGAAAAAGAACAACATCAAATTGTATGTACGCAGAGTTTTCATCATGGATAACTGTGAGGAGCTAATCCCTGAATATCTGAACTTCATTAGAGGGGTGGTAGACTCGGAGGATCTCCCTCTAAACATATCCCGTGAGATGTTGCAACAAAGCAAAATTTTGAAAGTTATCAGGAAGAATTTGGTCAAAAAATGCTTAGAACTCTTTACTGAACTGGCGGAAGATAAAGAGAACTACAAGAAATTCTATGAGCAGTTCTCTAAAAACATAAAGCTTGGAATACACGAAGACTCTCAAAATCGGAAGAAGCTTTCAGAGCTGTTAAGGTACTACACATCTGCCTCTGGTGATGAGATGGTTTCTCTCAAGGACTACTGCACCAGAATGAAGGAGAACCAGAAACATATCTATTATATCACAGGTGAGACCAAGGACCAGGTAGCTAACTCAGCCTTTGTGGAACGTCTTCGGAAACATGGCTTAGAAGTGATCTATATGATTGAGCCCATTGATGAGTACTGTGTCCAACAGCTGAAGGAATTTGAGGGGAAGACTTTAGTGTCAGTCACCAAAGAAGGCCTGGAACTTCCAGAGGATGAAGAAGAGAAAAAGAAGCAGGAAGAGAAAAAAACAAAGTTTGAGAACCTCTGCAAAATCATGAAAGACATATTGGAGAAAAAAGTTGAAAAGGTGGTTGTGTCAAACCGATTGGTGACATCTCCATGCTGTATTGTCACAAGCACATATGGCTGGACAGCAAACATGGAGAGAATCATGAAAGCTCAAGCCCTAAGAGACAACTCAACAATGGGTTACATGGCAGCAAAGAAACACCTGGAGATAAACCCTGACCATTCCATTATTGAGACCTTAAGGCAAAAGGCAGAGGCTGATAAGAACGACAAGTCTGTGAAGGATCTGGTCATCTTGCTTTATGAAACTGCGCTCCTGTCTTCTGGCTTCAGTCTGGAAGATCCCCAGACACATGCTAACAGGATCTACAGGATGATCAAACTTGGTCTGGGTATTGATGAAGATGACCCTACTGCTGATGATACCAGTGCTGCTGTAACTGAAGAAATGCCACCCCTTGAAGGAGATGACGACACATCACGCATGGAAGAAGTAGACTAATCTCTGGCTGAGGGATGACTTACCTGTTCAGTACTCTACAATTCCTCTGATAATATATTTTCAAGGATGTTTTTCTTTATTTTTGTTAATATTAAAAAGTCTGTATGGCATGACAACTACTTTAAGGGGAAGATAAGATTTCTGTCTACTAAGTGATGCTGTGATACCTTAGGCACTAAAGCAGAGCTAGTAATGCTTTTTGAGTTTCATGTTGGTTTATTTTCACAGATTGGGGTAACGTGCACTGTAAGACGTATGTAACATGATGTTAACTTTGTGGTCTAAAGTGTTTAGCTGTCAAGCCGGATGCCTAAGTAGACCAAATCTTGTTATTGAAGTGTTCTGAGCTGTATCTTGATGTTTAGAAAAGTATTCGTTACATCTTGTAGGATCTACTTTTTGAACTTTTCATTCCCTGTAGTTGACAATTCTGCATGTACTAGTCCTCTAGAAATAGGTTAAACTGAAGCAACTTGATGGAAGGATCTCTCCACAGGGCTTGTTTTCCAAAGAAAAGTATTGTTTGGAGGAGCAAAGTTAAAAGCCTACCTAAGCATATCGTAAAGCTGTTCAAAAATAACTCAGACCCAGTCTTGTGGATGGAAATGTAGTGCTCGAGTCACATTCTGCTTAAAGTTGTAACAAATACAGATGAGTTAAAAGATATTGTGTGACAGTGTCTTATTTAGGGGGAAAGGGGAGTATCTGGATGACAGTTAGTGCCAAAATGTAAAACATGAGGCGCTAGCAGGAGATGGTTAAACACTAGCTGCTCCAAGGGTTGACATGGTCTTCCCAGCATGTACTCAGCAGGTGTGGGGTGGAGCACACGTAGGCACAGAAAACAGGAATGCAGACAACATGCATCCCCTGCGTCCATGAGTTACATGTGTTCTCTTAGTGTCCACGTTGTTTTGATGTTATTCATGGAATACCTTCTGTGTTAAATACAGTCACTTAATTCCTTGGCCTTA |
hsa_circ_0033397 | GTGGTTGTGTCAAACCGATTGGTGACATCTCCATGCTGTATTGTCACAAGCACATATGGCTGGACAGCAAACATGGAGAGAATCATGAAAGCTCAAGCCCTAAGAGACAACTCAACAATGGGTTACATGGCAGCAAAGAAACACCTGGAGATAAACCCTGACCATTCCATTATTGAGACCTTAAGGCAAAAGGCAGAGGCTGATAAGAACGACAAGTCTGTGAAGGATCTGGTCATCTTGCTTTATGAAACTGCGCTCCTGTCTTCTGGCTTCAGTCTGGAAGATCCCCAGACACATGCTAACAGGATCTACAGGATGATCAAACTTGGTCTGG |
hsa_circ_0033398 | GTGGAGAAGGAACGTGATAAAGAAGTAAGCGATGATGAGGCTGAAGAAAAGGAAGACAAAGAAGAAGAAAAAGAAAAAGAAGAGAAAGAGTCGGAAGACAAACCTGAAATTGAAGATGTTGGTTCTGATGAGGAAGAAGAAAAGAAGGATGGTGACAAGAAGAAGAAGAAGAAGATTAAGGAAAAGTACATCGATCAAGAAGAGCTCAACAAAACAAAGCCCATCTGGACCAGAAATCCCGACGATATTACTAATGAGGAGTACGGAGAATTCTATAAGAGCTTGACCAATGACTGGGAAGATCACTTGGCAGTGAAGCATTTTTCAGTTGAAGGACAGTTGGAATTCAGAGCCCTTCTATTTGTCCCACGACGTGCTCCTTTTGATCTGTTTGAAAACAGAAAGAAAAAGAACAACATCAAATTGTATGTACGCAGAGTTTTCATCATGGATAACTGTGAGGAGCTAATCCCTGAATATCTGAACTTCATTAGAGGGGTGGTAGACTCGGAGGATCTCCCTCTAAACATATCCCGTGAGATGTTGCAACAAAGCAAAATTTTGAAAGTTATCAGGAAGAATTTGGTCAAAAAATGCTTAGAACTCTTTACTGAACTGGCGGAAGATAAAGAGAACTACAAGAAATTCTATGAGCAGTTCTCTAAAAACATAAAGCTTGGAATACACGAAGACTCTCAAAATCGGAAGAAGCTTTCAGAGCTGTTAAGGTACTACACATCTGCCTCTGGTGATGAGATGGTTTCTCTCAAGGACTACTGCACCAGAATGAAGGAGAACCAGAAACATATCTATTATATCACAGGTGAGACCAAGGACCAGGTAGCTAACTCAGCCTTTGTGGAACGTCTTCGGAAACATGGCTTAGAAGTGATCTATATGATTGAGCCCATTGATGAGTACTGTGTCCAACAGCTGAAGGAATTTGAGGGGAAGACTTTAGTGTCAGTCACCAAAGAAGGCCTGGAACTTCCAGAGGATGAAGAAGAGAAAAAGAAGCAGGAAGAGAAAAAAACAAAGTTTGAGAACCTCTGCAAAATCATGAAAGACATATTGGAGAAAAAAGTTGAAAAGGTGGTTGTGTCAAACCGATTGGTGACATCTCCATGCTGTATTGTCACAAGCACATATGGCTGGACAGCAAACATGGAGAGAATCATGAAAGCTCAAGCCCTAAGAGACAACTCAACAATGGGTTACATGGCAGCAAAGAAACACCTGGAGATAAACCCTGACCATTCCATTATTGAGACCTTAAGGCAAAAGGCAGAGGCTGATAAGAACGACAAGTCTGTGAAGGATCTGGTCATCTTGCTTTATGAAACTGCGCTCCTGTCTTCTGGCTTCAGTCTGGAAGATCCCCAGACACATGCTAACAGGATCTACAGGATGATCAAACTTGGTCTGG |
hsa_circ_0033399 | GTGAACCTATGGGTCGTGGAACAAAAGTTATCCTACACCTGAAAGAAGACCAAACTGAGTACTTGGAGGAACGAAGAATAAAGGAGATTGTGAAGAAACATTCTCAGTTTATTGGATATCCCATTACTCTTTTTGTGGAGAAGGAACGTGATAAAGAAGTAAGCGATGATGAGGCTGAAGAAAAGGAAGACAAAGAAGAAGAAAAAGAAAAAGAAGAGAAAGAGTCGGAAGACAAACCTGAAATTGAAGATGTTGGTTCTGATGAGGAAGAAGAAAAGAAGGATGGTGACAAGAAGAAGAAGAAGAAGATTAAGGAAAAGTACATCGATCAAGAAGAGCTCAACAAAACAAAGCCCATCTGGACCAGAAATCCCGACGATATTACTAATGAGGAGTACGGAGAATTCTATAAGAGCTTGACCAATGACTGGGAAGATCACTTGGCAGTGAAGCATTTTTCAGTTGAAGGACAGTTGGAATTCAGAGCCCTTCTATTTGTCCCACGACGTGCTCCTTTTGATCTGTTTGAAAACAGAAAGAAAAAGAACAACATCAAATTGTATGTACGCAGAGTTTTCATCATGGATAACTGTGAGGAGCTAATCCCTGAATATCTGAACTTCATTAGAGGGGTGGTAGACTCGGAGGATCTCCCTCTAAACATATCCCGTGAGATGTTGCAACAAAGCAAAATTTTGAAAGTTATCAGGAAGAATTTGGTCAAAAAATGCTTAGAACTCTTTACTGAACTGGCGGAAGATAAAGAGAACTACAAGAAATTCTATGAGCAGTTCTCTAAAAACATAAAGCTTGGAATACACGAAGACTCTCAAAATCGGAAGAAGCTTTCAGAGCTGTTAAGGTACTACACATCTGCCTCTGGTGATGAGATGGTTTCTCTCAAGGACTACTGCACCAGAATGAAGGAGAACCAGAAACATATCTATTATATCACAG |
hsa_circ_0033340 | GTCCATAGGAAGTACACAGGGGAAGACTTTGATGAAGATCTACGGACAGTGTTGAGACGTTCTGGCTGTAAAAATGAAAAGATAGCATTTATAATGGATGAATCTAATGTGTTAGATTCTGGATTCCTGGAGCGAATGAATACCCTTCTGGCCAATGGAGAGGTGCCTGGTCTCTTTGAAGGAGACGAGTATGCCACCTTGATGACGCAGTGCAAAGAGGGGGCACAGAAGGAAGGCCTGATGCTGGACTCGCACGAGGAGCTCTACAAGTGGTTCACTAGCCAGGTTATCCGCAACCTCCACGTCGTGTTCACCATGAACCCGTCCTCGGAGGGACTCAAGGACCGGGCAGCTACATCACCAGCACTTTTCAACAG |
hsa_circ_0033385 | GTATTGATGAAGATGACCCTACTGCTGATGATACCAGTGCTGCTGTAACTGAAGAAATGCCACCCCTTGAAGGAGATGACGACACATCACGCATGGAAGAAGTAGACTAATCTCTGGCTGAGGGATGACTTACCTGTTCAGTACTCTACAATTCCTCTGATAATATATTTTCAAGGATGTTTTTCTTTATTTTTGTTAATATTAAAAAGTCTGTATGGCATGACAACTACTTTAAGGGGAAGATAAGATTTCTGTCTACTAAGTGATGCTGTGATACCTTAGGCACTAAAGCAGAGCTAGTAATGCTTTTTGAGTTTCATGTTGGTTTATTTTCACAGATTGGGGTAACGTGCACTGTAAGACGTATGTAACATGATGTTAACTTTGTGGTCTAAAGTGTTTAGCTGTCAAGCCGGATGCCTAAGTAGACCAAATCTTGTTATTGAAGTGTTCTGAGCTGTATCTTGATGTTTAGAAAAGTATTCGTTACATCTTGTAGGATCTACTTTTTGAACTTTTCATTCCCTGTAGTTGACAATTCTGCATGTACTAGTCCTCTAGAAATAGGTTAAACTGAAGCAACTTGATGGAAGGATCTCTCCACAGGGCTTGTTTTCCAAAGAAAAGTATTGTTTGGAGGAGCAAAGTTAAAAGCCTACCTAAGCATATCGTAAAGCTGTTCAAAAATAACTCAGACCCAGTCTTGTGGATGGAAATGTAGTGCTCGAGTCACATTCTGCTTAAAGTTGTAACAAATACAGATGAGTTAAAAGATATTGTGTGACAGTGTCTTATTTAGGGGGAAAGGGGAGTATCTGGATGACAGTTAGTGCCAAAATGTAAAACATGAGGCGCTAGCAGGAGATGGTTAAACACTAGCTGCTCCAAGGGTTGACATGGTCTTCCCAGCATGTACTCAGCAGGTGTGGGGTGGAGCACACGTAGGCACAGAAAACAGGAATGCAGACAACATGCATCCCCTGCGTCCATGAGTTACATGTGTTCTCTTAGTGTCCACGTTGTTTTGATGTTATTCATGGAATACCTTCTGTGTTAAATACAGTCACTTAATTCCTTGGCCTTA |
sh-NC | CCGGGTGGTTGTGT TAAGGCCAAGCTCGAGCTTGGCCTTAACACAACCACTTTTTG |
sh-circ-HSP90A#1 | CCGGTTCCTTGGCCTTAGTGGTTGTCTCGAGACAACCACTAAGGCCAAGGAATTTTTG |
sh-circ-HSP90A#2 | CCGGTGGCCTTAGTGGTTGTGTCAACTCGAGTTGACACAACCACTAAGGCCATTTTTG |
sh-HSP90A#1 | CACCATCAAACGAGCATGTCTACACCTCGAGGTGTAGACATGCTCGTTTGA |
sh-HSP90A#2 | CACCGTGTTTGTGCGAAGATGTTGCTCTCGAGAGCAACATCTTCGCACAAACA |
pcDNA3.1/HSP90A | atggcttccactgtgacacccgaggttcgctgggcccagcgctcttctgctaccgatcccgagaacaacttcatctacctcaccattagcgttcccgacgtccctacttccaaccttaagctcgaccttaagcccactggtctcgtcttcaccggccactccgacaccctcaagaagacctaccatgtcgagcttgagttctacgccgaaattgaccctgctgcgagccaggtccaccacacggcccgtgatgtcgagatgaagctccgcaagaaggagcttgatgctcattactggccccgtctcctcaaggagcccaagaaggttcacttcctcaagaccgactttgacaagtgggttgatgaggacgagcagcacgaggccgctgaggatgacttcagcaactttggcggtatggaagggatgggtggaatgcctggtatgggtggcatgaatggcatgggtggtatgggtggtgacttcggcggtatcgacttctccaagttgggcggtgctggtttgcccggcggcgacgatgaggaagactccgacgatgacatgcctcctctcgagggtgagggcgaggctgataaggccgaggaggcaaaggatgccaaggagactgtcgacacgtcaaaggaggctgcgtaa |
pcDNA3.1/PD-L1 | atggagcagacttttctcttggttttacatgtagtcttatggccaactcttgcagccttgttcacagtggaggtggacagtctctcacatgtggcagagttctacggtgatgtcaccatgggctgcaggttccaacctgggagctgggacccgaacctgtcagtgatatggcaacgggtccagcctcttccagatgtagaggtgtacaggctggataacggacaggagaacctcacttctcagaatttccagtaccgcggcagggcacggttggtgtcggaggagctgaccaatggctgggccaagctacatgtgtccaggctgaggatcaacgactctggggtgtacagatgtcttgtggaaatggggggagctgattataaacagaccactttgactgtcaaagctacctataagactatcattaaaagcatgcagagacgtgggggaggtgaggtggagctggcctgtgagtctgagggctatcctcttgccacaatcaactggagagacaagagtctcaggaacatcaaatccaacgacaccgttgtgaaaactccaaaccagcttttccatgtcaccagcaaaataacggtcaaatactctgagaaaaacaactatacatgtgccttcgtggagaaaggggaagctccaaagggtccatcagccaggtttgacatcccagatgaaatacctgtgattgagagtaaacctaacaccctttctattgtattgggcacgacattgacggtggctatgatcattgtagctaccatcttcgggtatcgcagacagaaaggtaggctcaggaccctcaaactctaa |
bio-circ-HSP90A | ACACAACCACTAAGGCCAAG-biotin |
NC mimics | acacagcaguugucaugauauu |
miR-424-5p mimics | cagcagcaauucauguuuugaa |
NC inhibitor | cacauguuaauaugcugcugaa |
miR-424-5p inhibitor | uucaaaacaugaauugcugcug |
Cell transfection
Specific shRNAs against circ-HSP90A or HSP90A or USP30, sh-NC, pcDNA3.1 vector targeting HSP90A or PD-L1, and the empty vector were all procured from Genechen (Shanghai, China). MiR-424-5p mimics/inhibitor and NC mimics/inhibitor were offered by GenePharma (Shanghai, China). Plasmid transfection was performed by means of Lipotransfectamine 3000 (Thermo Fisher Scientific). All experiments were performed at least three times.
Cell counting kit-8 (CCK-8)
Transfected cells were planted in 96-well plates for incubation. Next, cells were treated with CCK-8 solution (Dojindo, Tokyo, Japan). The absorbance was observed at 450 nm. Three experiments were required.
Colony formation
Transfected cells were grown in 6-well plates and cultured for 8 days. Afterward, the number of cells was counted after fixation and staining. This experiment was in triplicate.
Wound healing
Transfected cells were plated into 24-well plates for incubation. Then, a scratch was made with a plastic tip. The time of wound infliction was considered as 0 h, and wound closure was photographed after 24 h using a microscope. Three experiments were required.
Transwell
A 24-well transwell chamber (BD Biosciences, USA) was adopted for cell invasion assay and performed three times. Transfected cells in serum-free medium (Gibco) were placed into upper chambers pre-coated with Matrigel (BD Biosciences). The lower chambers were placed with medium containing 20% FBS (Gibco). After 48 h, the non-invaded cells were wiped off, and the invaded cells through the Matrigel were fixed and stained and then observed via a microscope (Olympus, Japan). Three experiments were required.
Sphere formation
Transfected cells were plated on ultra-low attachment plates (Corning, NY, USA) in serum-free medium containing EGF (20 ng/mL, Invitrogen, USA), FGF (20 ng/mL, Invitrogen, USA), heparin (4 mg/mL, Sigma-Aldrich, Germany) and B27 (2%, Invitrogen, USA). After 14 days of incubation, the sphere number and size were analyzed. All experiments were performed for 3 times.
Luciferase reporter assay
Cignal Finder Reporter Array (336,841, QIAGEN, Dusseldorf, Germany) was used to detect the possible signaling pathway downstream of circRNA. Transfected cells were treated with the various luciferase reporter constructs to examine the luciferase activities of the Notch pathway, the Wnt pathway, the STAT3 pathway, the NF-κB pathway, the PI3K/AKT pathway, the NRF2 pathway, the Hedgehog pathway, the MAPK/JNK pathway, and the MAPK/ERK pathway, respectively. Besides, transfected cells were incubated with the pGL3-basic reporter vectors (Promega, Madison, WI, USA) including PD-L1 promoter. Moreover, the pmirGLO dual-luciferase vectors (Promega, Madison, WI, USA) of circ-HSP90A or PD-L1 3′UTR containing miR-424-5p sequences were co-transfection with miR-424-5p mimics or NC mimics into cells. Luciferase activities were measured via a luciferase reporter assay kit (Promega). The experiment was in triplicate.
Western blot
RIPA lysis buffer (Beyotime) was applied to extract total protein. Then, the protein was separated by 10% SDS-PAGE gel and moved onto PVDF membranes (Millipore, MA, USA). The membranes were incubated with primary antibodies including anti-p-STAT3 (Abcam, 1/2000), anti-STAT3 (Abcam, 1/1000), anti-c-Myc (Abcam, 1/1000), anti-MMP2 (Abcam, 1/1000), anti-MMP9 (Abcam, 1/1000), anti-HSP90 (Abcam, 1/10000), anti-USP30 (Abcam, 1/500), anti-PD-L1 (Abcam, 1/1000) and anti-GAPDH (Abcam, 1/1000) after blocking. Next, the membranes were incubated with secondary antibodies. The immunoblots were visualized through ECL chemiluminescence detection system (Thermo Scientific). The experiment was performed thrice.
Ubiquitination assay
Ubiquitin and the indicated plasmids were transfected into cells for 48 h. Then cells were immunoprecipitated with the HSP90A antibodies together with protein A/G beads (Life Technologies) with rotation and then examined by western blot. Anti-Ubiquitin (ab134953), anti-HSP90A (ab203126), and anti-GAPDH (ab181602) were all purchased from Abcam (Cambridge, MA, USA). Three experiments were required.
RNA pull down assay
Using a Pierce Magnetic RNA Protein Pull-Down Kit (Thermo Fisher Scientific), we explored circ-HSP90A-interacting proteins. Protein extracts from cells were processed with biotinylated circ-HSP90A probes and beads for 1 h of incubation. The RNA-complex was monitored by western blot.
For detecting the interaction between circ-HSP90A and miRNAs, cell lysates were transcribed with biotinylated circ-HSP90A and then treated with streptavidin beads. RT-qPCR was employed to examine the enrichment of selected miRNAs after washing. All experiments were performed in triplicate.
RNA immunoprecipitation (RIP)
This assay was implemented through a RIP™ RNA-Binding Protein Immunoprecipitation Kit (Millipore). Transfected cells were lysed and incubation with RIP buffer which contained magnetic beads. The beads were conjugated with anti-Ago2 antibody or anti-USP30 or anti-IgG. Then, the cells samples were treated with Proteinase K and the immunoprecipitated RNA was purified and then detected by RT-qPCR. The experiment was taken for three times.
Flow cytometry analysis
Transfected cells were co-cultured with CD8+ T cells, and flow cytometry was then conducted for assessing the percentage of CD8+ T cells or CD8+ T-cell apoptosis. All experiments were performed thrice.
Subcellular fractionation
Cytoplasmic or nuclear RNA was isolated from cells and purified employing a PARIS Kit (Ambion). The expression level of circ-HSP90A was examined by RT-qPCR. All experiments were performed thrice.
Fluorescent in situ hybridization (FISH)
The RNA FISH probe designed for circ-HSP90A was purchased from RiboBio. Cell nuclei were counterstained with DAPI for observation under a microscope. All experiments were performed thrice.
Statistical analysis
Data were exhibited as mean ± SD and analyzed using SPSS 22.0. Variance analyses were implemented via Student’s t test or one-way ANOVA. P < 0.05 was considered statistically significant. All assays were implemented thrice.
Results
Circ-HSP90A expression and function in NSCLC cells
A current study has indicated that HSP90A is abundant in NSCLC patients [20]. To search for circRNAs linked to NSCLC, we selected 16 circRNAs derived from HSP90A and applied RT-qPCR to measure their expression levels in five NSCLC cells (H1299, A549, PC9, CAL-12T, and H1915) and normal human bronchial epithelial cells (BEAS-2B). As revealed in Figure S1A-O and Fig. 1A, only up-regulation of hsa_circ_0033393 (named circ-HSP90A) was observed in all selected NSCLC cells compared with BEAS-2B cells, mirroring a potential role in NSCLC. As the expression was most obviously shown in H1299 and A549 cells, these two cell lines were chosen as the subject. Before probing circ-HSP90A function in NSCLC, we firstly validated the character of circ-HSP90A through several assays. Firstly, the head-to-tail splicing of circ-HSP90A is displayed in Figure S2A. Then, we adopted divergent primers to amplify circ-HSP90A and adopted cDNA and genomic DNA (gDNA) as templates. The circ-HSP90A magnification product was only discovered in cDNA by divergent primers rather than in gDNA (Figure S2B). Moreover, the fragment of linear-HSP90A was reduced after RNase R treatment, whereas circ-HSP90A was unchanged after RNase R treatment (Figure S2C). In addition, we discovered that circ-HSP90A was more stable than the linear form of HSP90A after treating actinomycin D (Act D) (Figure S2D). All above data suggested that circ-HSP90A was stably overexpressed in NSCLC cells. Subsequently, we established stable circ-HSP90A knockdown vectors and applied RT-qPCR to verify circ-HSP90A silence efficiency (Fig. 1B). Followed by CCK-8 and colony formation experiments, we found that circ-HSP90A depletion obviously inhibited two NSCLC cells proliferation (Fig. 1C, D). Besides, the migratory and invasive capacities were repressed when circ-HSP90A was down-regulated in two NSCLC cells, as evidenced by wound healing and transwell assays (Fig. 1E, F). At the same time, we tried to examine the stemness of H1299 and A549 cells under circ-HSP90A silence. Sphere formation assays depicted that circ-HSP90A deficiency reduced the sphere formation efficiency (Fig. 1G).
Circ-HSP90A stabilizes HSP90A protein in NSCLC cells
Increasing reports have indicated that circRNAs can activate the signaling pathways to promote the progression of cancers, NSCLC included [21]. To assess whether circ-HSP90A facilitates NSCLC progression via regulating some certain pathways, we adopted a luciferase reporter assay kit to examine the activities of several common pathways in HEK293T and A549 cells transfected with circ-HSP90A-shRNAs. Compared to the control group, circ-HSP90A silence decreased the activity of the STAT3 pathway, whereas had no impacts on that of other pathways (Fig. 2A). Western blot analysis further validated that circ-HSP90A deletion reduced phosphorylation level of STAT3 as well as the levels of downstream genes such as c-Myc, MMP2 and MMP9 (Fig. 2B), suggesting that circ-HSP90A could activate the STAT3 pathway in NSCLC cells. Besides, recent studies have revealed that circRNAs exhibit diverse biological functions via regulating their host genes [22]. Thus, we assumed that circ-HSP90A might influence the STAT3 pathway and NSCLC progression via regulating HSP90A. We firstly measured HSP90A expression in five NSCLC cells. In contrast to BEAS-2B cells, HSP90A presented a high expression level in all NSCLC cells (Fig. 2C). We then detected HSP90A mRNA and protein levels in two NSCLC cells after transfection with circ-HSP90A-shRNAs. Intriguingly, we found that circ-HSP90A depletion could not influence HSP90A mRNA level but significantly decreased the protein level of HSP90A (Fig. 2D, E). We next treated both NSCLC cells with the protein synthesis inhibitor CHX and found that the stability of HSP90A protein was restrained after circ-HSP90A knockdown (Fig. 2F). Besides, we confirmed that proteasome inhibitor MG132 could weaken this phenomenon (Fig. 2G). Moreover, the ubiquitination of HSP90A protein was increased when circ-HSP90A was silenced in two NSCLC cells (Fig. 2H). To verify whether HSP90A promotes NSCLC cells proliferation, migration, invasion and stemness, we constructed HSP90A-knockdown H1299 and A549 cells (Figure S3A). It was manifested that HSP90A silence hindered two NSCLC cells proliferation (Figure S3B-SC). Consistently, the migratory and invasive abilities were inhibited in wound healing and transwell assays when HSP90A was down-regulated (Figure S3D, E). Additionally, sphere formation assays further validated that HSP90A depletion repressed the stemness of H1299 and A549 cells (Figure S3F). Moreover, the correlation between circ-HSP90A and HSP90A is detected and shown in Figure S3G.
Circ-HSP90A recruits USP30 to de-ubiquitinate and stabilizes HSP90A protein
To unveil the molecular mechanism that why circ-HSP90A could stabilize HSP90A protein in NSCLC cells, RNA pull down assay was implemented to search out circ-HSP90A-interacting proteins. A specific band exhibited on the electrophoretic gel at 59 kDa in bio-circ-HSP90A WT compared to bio-circ-HSP90A-MUT (Fig. 3A). We then identified that this protein was USP30 after mass spectrometry. We further confirmed the combination between circ-HSP90A and USP30 by an independent immunoblot and a RIP assay (Fig. 3B, C). Besides, we also proved the combination of HSP90A and USP30 via RIP assays (Fig. 3D). More importantly, this bond was attenuated when circ-HSP90A expression was declined in H1299 and A549 cells (Fig. 3E). USP30 is an enzyme that de-ubiquitinates proteins [23]. Thus, we conjectured that circ-HSP90A might recruit USP30 to de-ubiquitinate and stabilize HSP90A protein. To validate our assumption, we reduced USP30 expression and measured the stability of HSP90A protein in H1299 and A549 cells treated with CHX (Fig. 3F, G). The results showed that USP30 silence obviously decreased the stability of HSP90A protein (Fig. 3H). At the same time, this phenomenon was reversed after MG132 treatment (Fig. 3I). As expected, USP30 reduction increased the ubiquitination of HSP90A protein (Fig. 3J).
Circ-HSP90A influences the STAT3 pathway and NSCLC progression via HSP90A
After that, we investigated whether circ-HSP90A influences the STAT3 pathway and NSCLC progression via regulating HSP90A. We stably overexpressed HSP90A (Fig. 4A) and found that HSP90A overexpression reversed the reduced phosphorylation level of STAT3 as well as the levels of downstream genes such as c-Myc, MMP2, and MMP9 caused by circ-HSP90A silence (Fig. 4B). Besides, the reduced proliferation in circ-HSP90A-depleted H1299 and A549 cells was almost restored after HSP90A elevation together (Fig. 4C, D). Moreover, when HSP90A was up-regulated simultaneously, the repressive migration and invasion in two NSCLC cells after circ-HSP90A down-regulation were offset (Fig. 4E, F). Additionally, the inhibited stemness in circ-HSP90A-shRNA transfected cells was abolished after co-transfection of pcDNA3.1/HSP90A (Fig. 4G).
Circ-HSP90A triggers CD8+T cells apoptosis through PD-L1
As report goes, tumor cells interact with and hinder the cytotoxic functions of CD8+ T cells in tumor microenvironment [24]. Hence, we speculated that circ-HSP90A might affect CD8+ T cells in NSCLC. To simulate the tumor microenvironment, the NSCLC cells were co-cultured with CD8+ T cells. The results from flow cytometry analysis showed that the percentage of CD8+ T cells was enhanced while CD8+ T cells apoptosis was declined after circ-HSP90A was down-regulated in H1299 and A549 cells (Fig. 5A, B). Besides, due to the fact that PD-1/PD-L1 interaction can repress CD8+ T cells activity and reinforce the immune evasion in tumors [25], we further supposed that circ-HSP90A might influence the alteration of CD8+ T cells via PD-1/PD-L1 checkpoint. In order to certify our assumption, we firstly detected PD-L1 mRNA and protein levels in circ-HSP90A-shRNAs transfected cells using RT-qPCR and western blot. As a result, we found that the mRNA and protein levels of PD-L1 were reduced upon circ-HSP90A silence (Fig. 5C, D). Subsequently, we overexpressed PD-L1 and severally co-transfected them together with sh-circ-HSP90A#1 into the co-culture system (Fig. 5E, F). We found that the reduced ratio of CD8+ T cells as well as the induced CD8+ T cells apoptosis caused by circ-HSP90A silence was reversed after co-transfection of pcDNA3.1/PC-L1 (Fig. 5G, H).
Circ-HSP90A promotes the immune evasion of NSCLC via sponging miR-424-5p to up-regulate PD-L1
Furthermore, we investigated how circ-HSP90A regulates PD-1/PD-L1 immune checkpoint in NSCLC cells. Many studies have evidenced that the localization of circRNAs within cells is the main determinant of their molecular functions [26]. Based on subcellular fractionation and FISH experiments, we identified that the cellular location of circ-HSP90A was in the cytoplasm (Figure S4A, B). As is known to all, cytoplasmic circRNAs can interact with miRNAs to regulate mRNA expression. To test whether circ-HSP90A regulates PD-L1 expression via binding to miRNAs, RIP assays were carried out. It demonstrated that circ-HSP90A and PD-L1 were both enriched in Ago2 antibody (Figure S4C). At the same time, we ruled out the transcriptional regulation of PD-L1 influenced by circ-HSP90A, for that circ-HSP90A silence could not affect the luciferase activity of PD-L1 promoter (Figure S4D). Therefore, we continued to explore the possible miRNAs combined with both circ-HSP90A and PD-L1. Through starBase (http://starbase.sysu.edu.cn) database, 12 miRNAs were observed (Fig. 6A). To confirm the interaction between circ-HSP90A and miRNAs, a biotinylated circ-HSP90A-specific probe was designed to perform RNA pull down assay in two NSCLC cells. The result displayed that only miR-424-5p was markedly enriched, while other irrelevant miRNAs were not (Fig. 6B). Thus, miR-424-5p was chosen for subsequent analyses. The separate binding sites of miR-424-5p and circ-HSP90A along with the mutant sequences are shown in Fig. 6C. To validate the effectiveness of these binding sites, we increased miR-424-5p expression (Figure S5A) and constructed wild-type and mutant pmirGLO-circ-HSP90A vectors incorporating miR-424-5p binding sites for dual luciferase reporter assays. The results manifested that enforced miR-424-5p expression lessened the activity of circ-HSP90A-WT but not circ-HSP90A-MUT (Fig. 6D). Similarly, the base pairing of miR-424-5p and PD-L1 along with the mutant fragments is presented in Fig. 6E, and luciferase reporter assays further proved that miR-424-5p overexpression significantly reduced the luciferase activity of PD-L1 3′UTR-WT, but barely changed that of PD-L1 3′UTR-MUT (Fig. 6F). We further performed rescue assays to certify whether miR-424-5p is necessary for circ-HSP90A modulation on the immune evasion of NSCLC. Before this, we down-regulated miR-424-5p in two NSCLC cells (Figure S5B), and we found that in the co-culture system, the effects of enhanced ratio of CD8+ T cells and reduced CD8+ T cells apoptosis caused by circ-HSP90A silence were abrogated after co-transfecting of miR-424-5p inhibitor (Figure S5C, D).
Discussion
Emerging studies have demonstrated that circRNAs are momentous participants in the progression of human cancers, NSCLC included [27]. CircRNA_100876 predicts poor prognosis of NSCLC patients [28]. CircFOXM1 promotes proliferation of NSCLC cells via acting as a ceRNA to increase FAM83D [29]. Circ_0067934 contributes to NSCLC development by activating Wnt/β-catenin pathway [30]. Herein, we discovered that circ-HSP90A expression was elevated in NSCLC cells. This research for the first time discussed the relation between circ-HSP90A and NSCLC. Functional assays indicated that circ-HSP90A facilitated cell proliferation, migration, invasion, and stemness in NSCLC.
Mechanistically, this study unveiled that circ-HSP90A activated the STAT3 pathway in NSCLC. Excessive activation of the STAT3 signaling is strongly involved in many cancers, making activated STAT3 a promising possible therapeutic target supported by clinical studies [31]. Besides, many reports have displayed that circRNAs regulate the signaling pathways via affecting their host gene expression (32). To uncover the possible mechanism of STAT3 activation regulated by circ-HSP90A, our study investigated the interaction between circ-HSP90A and HSP90A and found that circ-HSP90A could stabilize HSP90A protein in NSCLC cells. HSP90A has been registered to work as an oncogene in hepatocellular carcinoma [33]. Likewise, our study also proved that HSP90A expression was increased in NSCLC cells and facilitated NSCLC progression.
A further finding in our study was that both circ-HSP90A and HSP90A bound to USP30 in NSCLC cells. USP30 is a type of deubiquitinase that can reverse ubiquitin modifications and is therefore considered as an essential modulator of the ubiquitin system [34]. Our study indicated for the first time that USP30 was physically associated with and stabilized USP30 by its deubiquitinase activity. Additionally, rescue assays were carried out to prove that circ-HSP90A promoted the STAT3 signaling and NSCLC progression via recruiting USP30 to stabilize HSP90A expression.
For all we know, tumor cells can modify the T cell activity to get out from the anti-tumor immune response and thereby promoting tumor cells survival [35]. Moreover, recent studies have proposed that tumor cells can cooperate and stimulate CD8+ T cells apoptosis to expedite tumor progression [36]. In the current study, we disclosed that circ-HSP90A down-regulation could induce CD8+ T cells activity while attenuate CD8+ T cells apoptosis. Moreover, accumulating evidences have demonstrated that PD-L1 and PD-1 are expressed in NSCLC and are related to the density of CD8+ T-cells, implying an adaptive immune resistance mechanism in NSCLC [37]. PD-L1 expression is majorly presented in tumor and immune cells and is correlated with PD-1 expression (38). In our study, we found that circ-HSP90A promoted CD8+ T cells apoptosis via up-regulating PD-L1 expression. As reported previously, circRNAs can modulate mRNA expression through sequestering miRNAs [39]. Also, circRNA-controlled ceRNA mechanism has been widely reported in NSCLC [40]. Consistently, our study found that circ-HSP90A promoted PD-L1 expression via sponging miR-424-5p. MiR-424-5p has been registered to be lowly expressed in NSCLC and inhibits the radiosensitivity of NSCLC [41]. Our study firstly showed that circ-HSP90A altered CD8+ T cell activity through binding to miR-424-5p. Taken together, targeting circ-HSP90A potentially promoted the effect of immunotherapy in NSCLC via PD-1/PD-L1.
Our research firstly disclosed that circ-HSP90A facilitated NSCLC cell proliferation, migration, invasion, and stemness via recruiting USP30 to stabilize HSP90A and activate the STAT3 pathway. At the same time, circ-HSP90A regulated miR-424-5p to activate PD-L1, resulting in the suppression of CD8+ T cells and the immune evasion of NSCLC cells (Fig. 7). All above findings implied that HSP90A might be a hopeful target for the immunotherapy via PD-L1/PD-1 blockade in NSCLC. However, our study also presented some limitations. First, the detail regulatory mechanism of why circ-HSP90A was up-regulated in the NSCLC is still unclear. More, the specific STAT3 phosphorylation site activated by circ-HSP90A is still not explained. In the future, both deficiencies will be studied in depth.
Supplementary Information
Below is the link to the electronic supplementary material.
Acknowledgements
Thanks go to all participants.
Author contributions
JL, JZ, and BH contributed to the conceptualization. JL, JZ, BH, CJ, XY, TJ, and XW were involved in the data curation. JL, JZ, BH, CJ, XY, TJ, and XW helped in the formal analysis. TJ and XW were involved in the investigation. TJ and XW contributed to the methodology. JL, JZ, and BH were involved in the project administration. TJ and XW contributed to software. JL, JZ, BH were involved in the supervision. JL, JZ, and Bengang Hui were involved in the validation. JL, JZ, and BH contributed to the visualization. JL, JZ, and BH were involved in writing—original draft preparation. JL, JZ, and BH contributed to writing—review and editing.
Funding
None.
Data availability
Data sharing is not applicable.
Declarations
Competing interests
No potential conflict of interest was reported by the authors.
Consent for publication
We hope it to be considered for publication in your journal. All authors agreed upon the publication of this manuscript.
Ethics approval and consent to participate
This article does not contain any studies with human participants or animals performed by any of the authors.
Footnotes
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Jie Lei, Jianfei Zhu and Bengang Hui are co-first authors.
Contributor Information
Tao Jiang, Email: jiangtaochest@163.com.
Xiaoping Wang, Email: wxpchest@fmmu.edu.cn.
References
- 1.Mao Y, Yang D, He J, Krasna MJ. Epidemiology of Lung Cancer. Surg Oncol Clin N Am. 2016;25:439–445. doi: 10.1016/j.soc.2016.02.001. [DOI] [PubMed] [Google Scholar]
- 2.Torre LA, Siegel RL, Jemal A. Lung cancer statistics. Adv Exp Med Biol. 2016;893:1–19. doi: 10.1007/978-3-319-24223-1_1. [DOI] [PubMed] [Google Scholar]
- 3.Bodor JN, Boumber Y, Borghaei H. Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC) Cancer. 2020;126:260–270. doi: 10.1002/cncr.32468. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Li X, Lian Z, Wang S, Xing L, Yu J. Interactions between EGFR and PD-1/PD-L1 pathway: Implications for treatment of NSCLC. Cancer Lett. 2018;418:1–9. doi: 10.1016/j.canlet.2018.01.005. [DOI] [PubMed] [Google Scholar]
- 5.Huang CY, Wang Y, Luo GY, Han F, Li YQ, Zhou ZG, Xu GL. Relationship between PD-L1 expression and CD8+ T-cell immune responses in hepatocellular carcinoma. J Immunother. 2017;40:323–333. doi: 10.1097/cji.0000000000000187. [DOI] [PubMed] [Google Scholar]
- 6.Li R, Jiang J, Shi H, Qian H, Zhang X, Xu W. CircRNA: a rising star in gastric cancer. Cell Mol Life Sci CMLS. 2020;77:1661–1680. doi: 10.1007/s00018-019-03345-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Chen LL, Yang L. Regulation of circRNA biogenesis. RNA Biol. 2015;12:381–388. doi: 10.1080/15476286.2015.1020271. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Shan C, Zhang Y, Hao X, Gao J, Chen X, Wang K. Biogenesis, functions and clinical significance of circRNAs in gastric cancer. Mol Cancer. 2019;18:136. doi: 10.1186/s12943-019-1069-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Chen B, Wei W, Huang X, et al. circEPSTI1 as a prognostic marker and mediator of triple-negative breast cancer progression. Theranostics. 2018;8:4003–4015. doi: 10.7150/thno.24106. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Sheng R, Li X, Wang Z, Wang X. Circular RNAs and their emerging roles as diagnostic and prognostic biomarkers in ovarian cancer. Cancer Lett. 2020;473:139–147. doi: 10.1016/j.canlet.2019.12.043. [DOI] [PubMed] [Google Scholar]
- 11.Li X, Yang L, Chen LL. The biogenesis, functions, and challenges of circular RNAs. Mol Cell. 2018;71:428–442. doi: 10.1016/j.molcel.2018.06.034. [DOI] [PubMed] [Google Scholar]
- 12.Chen L, Nan A, Zhang N, et al. Circular RNA 100146 functions as an oncogene through direct binding to miR-361-3p and miR-615-5p in non-small cell lung cancer. Mol Cancer. 2019;18:13. doi: 10.1186/s12943-019-0943-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Chen T, Yang Z, Liu C, Wang L, Yang J, Chen L, Li W. Circ_0078767 suppresses non-small-cell lung cancer by protecting RASSF1A expression via sponging miR-330-3p. Cell Prolif. 2019;52:e12548. doi: 10.1111/cpr.12548. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Hong W, Xue M, Jiang J, Zhang Y, Gao X. Circular RNA circ-CPA4/ let-7 miRNA/PD-L1 axis regulates cell growth, stemness, drug resistance and immune evasion in non-small cell lung cancer (NSCLC) J Exp Clin Cancer Res CR. 2020;39:149. doi: 10.1186/s13046-020-01648-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Xu X, Li D, Liu J, Ma Z, Huang H, Min L, Dai L, Dong S. Downregulation of PTPRK promotes cell proliferation and metastasis of NSCLC by enhancing STAT3 activation. Anal Cell Pathol (Amst) 2019;2019:4265040. doi: 10.1155/2019/4265040. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Yu H, Lee H, Herrmann A, Buettner R, Jove R. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat Rev Cancer. 2014;14:736–746. doi: 10.1038/nrc3818. [DOI] [PubMed] [Google Scholar]
- 17.Sun Z, Zeng L, Zhang M, Zhang Y, Yang N. PIM1 inhibitor synergizes the anti-tumor effect of osimertinib via STAT3 dephosphorylation in EGFR-mutant non-small cell lung cancer. Ann Transl Med. 2020;8:366. doi: 10.21037/atm.2020.02.43. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Dong Y, Xu T, Zhong S, Wang B, Zhang H, Wang X, Wang P, Li G, Yang S. Circ_0076305 regulates cisplatin resistance of non-small cell lung cancer via positively modulating STAT3 by sponging miR-296-5p. Life Sci. 2019;239:116984. doi: 10.1016/j.lfs.2019.116984. [DOI] [PubMed] [Google Scholar]
- 19.Chen X, Mao R, Su W, et al. Circular RNA circHIPK3 modulates autophagy via MIR124-3p-STAT3-PRKAA/AMPKα signaling in STK11 mutant lung cancer. Autophagy. 2020;16:659–671. doi: 10.1080/15548627.2019.1634945. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Zhong B, Shen J, Zhang C, Zhou G, Yu Y, Qin E, Tang J, Wu D, Liang X. Plasma heat shock protein 90 alpha: a valuable predictor of early chemotherapy effectiveness in advanced non-small-cell lung cancer. Med Sci Mon Int Med J Exp Clin Res. 2021;27:e924778. doi: 10.12659/msm.924778. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Wang Y, Xu R, Zhang D, et al. Circ-ZKSCAN1 regulates FAM83A expression and inactivates MAPK signaling by targeting miR-330–5p to promote non-small cell lung cancer progression. Transl Lung Cancer Res. 2019;8:862–875. doi: 10.21037/tlcr.2019.11.04. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Cai H, Li Y, Niringiyumukiza JD, Su P, Xiang W. Circular RNA involvement in aging: an emerging player with great potential. Mech Ageing Dev. 2019;178:16–24. doi: 10.1016/j.mad.2018.11.002. [DOI] [PubMed] [Google Scholar]
- 23.Kluge AF, Lagu BR, Maiti P, Jaleel M, Webb M, Malhotra J, Mallat A, Srinivas PA, Thompson JE. Novel highly selective inhibitors of ubiquitin specific protease 30 (USP30) accelerate mitophagy. Bioorg Med Chem Lett. 2018;28:2655–2659. doi: 10.1016/j.bmcl.2018.05.013. [DOI] [PubMed] [Google Scholar]
- 24.Davis RJ, Van Waes C, Allen CT. Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer. Oral Oncol. 2016;58:59–70. doi: 10.1016/j.oraloncology.2016.05.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Wu SP, Liao RQ, Tu HY, et al. Stromal PD-L1-positive regulatory T cells and PD-1-positive CD8-positive T cells define the response of different subsets of non-small cell lung cancer to PD-1/PD-L1 blockade immunotherapy. J Thor Oncol Off Publ Int Assoc Study Lung Cancer. 2018;13:521–532. doi: 10.1016/j.jtho.2017.11.132. [DOI] [PubMed] [Google Scholar]
- 26.Du WW, Zhang C, Yang W, Yong T, Awan FM, Yang BB. Identifying and characterizing circRNA-protein interaction. Theranostics. 2017;7:4183–4191. doi: 10.7150/thno.21299. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Zhang N, Nan A, Chen L, et al. Circular RNA circSATB2 promotes progression of non-small cell lung cancer cells. Mol Cancer. 2020;19:101. doi: 10.1186/s12943-020-01221-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Yao JT, Zhao SH, Liu QP, Lv MQ, Zhou DX, Liao ZJ, Nan KJ. Over-expression of CircRNA_100876 in non-small cell lung cancer and its prognostic value. Pathol Res Pract. 2017;213:453–456. doi: 10.1016/j.prp.2017.02.011. [DOI] [PubMed] [Google Scholar]
- 29.Yu C, Cheng Z, Cui S, et al. circFOXM1 promotes proliferation of non-small cell lung carcinoma cells by acting as a ceRNA to upregulate FAM83D. J Exp Clin Cancer Res CR. 2020;39:55. doi: 10.1186/s13046-020-01555-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Zhao M, Ma W, Ma C. Circ_0067934 promotes non-small cell lung cancer development by regulating miR-1182/KLF8 axis and activating Wnt/β-catenin pathway. Biomed Pharmacother Biomed Pharmacother. 2020;129:110461. doi: 10.1016/j.biopha.2020.110461. [DOI] [PubMed] [Google Scholar]
- 31.Yang L, Lin S, Xu L, Lin J, Zhao C, Huang X. Novel activators and small-molecule inhibitors of STAT3 in cancer. Cytokine Growth Factor Rev. 2019;49:10–22. doi: 10.1016/j.cytogfr.2019.10.005. [DOI] [PubMed] [Google Scholar]
- 32.Kong P, Yu Y, Wang L, et al. circ-Sirt1 controls NF-κB activation via sequence-specific interaction and enhancement of SIRT1 expression by binding to miR-132/212 in vascular smooth muscle cells. Nucleic Acids Res. 2019;47:3580–3593. doi: 10.1093/nar/gkz141. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Zhou Y, Deng X, Zang N, Li H, Li G, Li C, He M. Transcriptomic and proteomic investigation of HSP90A as a potential biomarker for HCC. Med Sci Monit Int Med J Exp Clin Res. 2015;21:4039–4049. doi: 10.12659/msm.896712. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Mevissen TET, Komander D. Mechanisms of deubiquitinase specificity and regulation. Annu Rev Biochem. 2017;86:159–192. doi: 10.1146/annurev-biochem-061516-044916. [DOI] [PubMed] [Google Scholar]
- 35.Kumar BV, Connors TJ, Farber DL. Human T cell development, localization, and function throughout life. Immunity. 2018;48:202–213. doi: 10.1016/j.immuni.2018.01.007. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Samji T, Khanna KM. Understanding memory CD8(+) T cells. Immunol Lett. 2017;185:32–39. doi: 10.1016/j.imlet.2017.02.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Tsoukalas N, Kiakou M, Tsapakidis K, Tolia M, Aravantinou-Fatorou E, Baxevanos P, Kyrgias G, Theocharis S. PD-1 and PD-L1 as immunotherapy targets and biomarkers in non-small cell lung cancer. J B.U.ON Off J Balkan Union Oncol. 2019;24:883–888. [PubMed] [Google Scholar]
- 38.Hamanishi J, Mandai M, Matsumura N, Abiko K, Baba T, Konishi I. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. Int J Clin Oncol. 2016;21:462–473. doi: 10.1007/s10147-016-0959-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Panda AC. Circular RNAs Act as miRNA Sponges. Adv Exp Med Biol. 2018;1087:67–79. doi: 10.1007/978-981-13-1426-1_6. [DOI] [PubMed] [Google Scholar]
- 40.Lv YS, Wang C, Li LX, Han S, Li Y. Effects of circRNA_103993 on the proliferation and apoptosis of NSCLC cells through miR-1271/ERG signaling pathway. Eur Rev Med Pharmacol Sci. 2020;24:8384–8393. doi: 10.26355/eurrev_202008_22635. [DOI] [PubMed] [Google Scholar]
- 41.Wang D, Hu Y. Long non-coding RNA PVT1 competitively binds MicroRNA-424-5p to regulate CARM1 in radiosensitivity of non-small-cell lung cancer. Mol Ther Nucleic Acids. 2019;16:130–140. doi: 10.1016/j.omtn.2018.12.006. [DOI] [PMC free article] [PubMed] [Google Scholar] [Retracted]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
Data sharing is not applicable.